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Sintesi 
Premesse scientifiche e metodologiche 
 
p63 (TP63/TP73L) è un omologo dell’oncosoppressore p53 e 
rappresenta il capostipite della famiglia genica di p53 (Yang A. 
et al., 1998; Osada M. et al., 1998). Il locus genico di p63, 
grazie all’utilizzo di due distinti promotori e ad eventi di splicing 
alternativo che si verificano a carico dell’estremità C-terminale, 
dà origine ad un totale di sei isoforme proteiche. Tre di queste 
possiedono all’estremità N-terminale un dominio di attivazione 
trascrizionale (TA) e sono funzionalmente simili a p53 
(TAp63 e ), le altre tre isoforme mancano del dominio TA e 
sono in grado di promuovere la sopravvivenza e la 
proliferazione cellulare (Np63 e  (Schmale et al., 1997). 
L’isoforma TAp63 è la più simile a p53, mentre le isoforme 
possiedono una notevole estensione al C-terminale, che 
include un dominio conservato di interazione proteina-proteina 
noto come ―Sterile Alpha Motif‖ (SAM). L’analisi dei topi 
knockout dimostra inequivocabilmente che p63 esercita un 
ruolo cruciale nello sviluppo dei tessuti epiteliali fra i quali 
l’epidermide e di organi derivati da interazioni epitelio-
mesenchima quali le ghiandole salivari, lacrimali, mammarie e 
la prostata (Yang A. et al., 1999). Np63 guida attivamente le 
fasi precoci dello sviluppo epidermico e governa il destino dei 
cheratinociti dello strato basale (Romano et al., 2009). I 
cheratinociti proliferanti dello strato basale, nell’epidermide 
dell’adulto, esprimono alti livelli di Np63 e l’iper-espressione 
di detta proteina è strettamente associata all’insorgenza 
nell’uomo di neoplasie a carico dell’epidermide stessa (Parsa et 
al., 1999). Tuttavia, il ruolo che  Np63riveste nello sviluppo e 
nella progressione del tumore, con particolare riguardo al 
processo di metastatizzazione, è piuttosto controverso. Per 
esempio, l’assenza dell’espressione di Np63  è caratteristica 
di tumori anaplastici della vescica, dell’uretere e del seno (Urist 
M.J. et al., 2002; Koga F. et al., 2003; Wang X. et al., 2002) e 
l’over-espressione di mutanti di splicing di Np63è stata 
osservata in numerosi carcinomi squamosi metastatici (Westfall 
and Pietenpol 2004). Inoltre, in cellule di carcinoma squamoso, 
il fattore di trascrizione Snail1 che promuove transizione 
epitelio-mesenchima (EMT), reprime Np63 favorendo 
dunque la metastatizzazione del tumore (Herf et al. 2010).  
L’attività funzionale di ogni proteina è legata alle sue interazioni 
con altre molecole e, nelle cellule eucariotiche, alla sua 
residenza nel corretto compartimento subcellulare poiché solo 
nel compartimento corretto troverà i ―partner‖ corretti. Nel 
laboratorio in cui ho svolto la mia tesi è stata intrapresa una 
linea di ricerca volta ad identificare gli interattori di p63 con 
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l’obiettivo di chiarire i meccanismi molecolari che coinvolgono 
Np63nello sviluppo e nella progressione del tumore. La 
comprensione dei meccanismi tramite i quali p63 controlla la 
genesi e progressione del tumore così come la patogenesi delle 
displasie ectodermiche costituirà una tappa fondamentale per lo 
sviluppo di nuovi farmaci e strategie terapeutiche. Mediante un 
approccio di proteomica funzionale, sono stati identificati 53 
potenziali interattori di Np63. Fra questi è inclusa 
l’oncoproteina YB-1. YB-1 è un importante marcatore tumorale 
per il cancro al seno, il carcinoma e l’adenocarcinoma 
polmonare, l’osteosarcoma, il carcinoma del colon-retto  ed il 
melanoma (Wu et al. 2007). 
L’obiettivo del mio lavoro è stato quello di comprendere il ruolo 
funzionale dell’associazione fra Np63 e YB-1. E’ già noto 
infatti, che YB-1 interagisca funzionalmente con p53 e con esso 
trasloca nel nucleo regolando l’espressione genica p53-
dipendente.  YB-1 controlla la trascrizione e la traduzione di 
molti fattori effettuando ―shuttling‖ tra nucleo e citoplasma. Nel 
nucleo YB-1 regola la trascrizione di geni coinvolti nella chemio-
resistenza, direttamente o attraverso l’associazione con p53, 
AP-1, Smad3 o p300 (Bader 2005),  e di geni  pro-proliferativi 
come cyclin A, cyclin B1, DNA pol  and PI3KCA, la subunità 
catalitica della fosfatidilinositolo-3-chinasi (PI3K) (Jurchott 2003; 
En-Nia 2005; Astanehe 2009). Nel citoplasma YB-1 svolge una 
funzione più strutturale ed è coinvolta nell’organizzazione 
spaziale dei complessi mRNPs (Skabkin, M. A 2004). In 
particolare, legandosi al Cap 5’ dei trascritti scalza i fattori di 
inizio della traduzione eIF4E ed eIF4G causando blocco della 
traduzione dell’mRNA. D’altra parte, YB-1 può legare ed 
attivare la traduzione cap-indipendente di specifici messageri 
coinvolti nell’EMT (transizione epitelio-mesenchima) come 
quello codificante SNAIL1, fattore di trascrizione che blocca 
l’espressione delle E-caderine (Battle et al., 2000). Nel cancro 
al seno, appunto, i livelli di espressione della proteina YB-1 
sono correlati ad una ridotta espressione di E-caderina e ad 
una prognosi infausta (Evdokimova 2009). Inoltre, la iper-
espressione di YB-1 in linee cellulari mammarie non invasive 
induce transizione epitelio-mesenchima (EMT) accompagnata 
da aumento del potenziale metastatico e ad un ridotto livello di 
proliferazione (Mouneimme G., 2009).  
La mia ricerca si è dunque articolata nelle seguenti quattro fasi: 
I. Studio dell’interazione tra le isoforme di p63 e YB-1 mediante 
approcci in vitro ed in diversi contesti cellulari (Saos2, U2OS, 
H1299, HaCat,  Hela, MDA231 e MCF7).  
II. Determinazione dell’effetto reciproco sui livelli di espressione, 
sulla stabilità e sulla localizzazione sub-cellulare attraverso 
iper-espressione e silencing specifico, immuno-localizzazione   
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e microscopia a fluorescenza, e misure di ―protein-decay‖ in 
cellule trattate con inibitori della sintesi proteica. 
III. Analisi dell’effetto dell’interazione con p63 sulle funzioni 
nucleari e citoplasmatiche di YB-1 mediante tecniche di 
immunoprecipitazione della cromatina e dell’RNA, tecniche di 
Real Time PCR e saggi luciferasi.  
IV. Determinazione dell’effetto di p63 e YB-1 sulla proliferazione e 
migrazione cellulare. Analisi di espressione in cheratinociti 
primari e di epitelio di cornea in fase rigenerativa e non.  
 
Risultati 
 
I. Mediante saggi di coimmunoprecipitazione, effettuati in diverse 
linee cellulari quali le Saos2, U2OS, H1299, HaCat, Hela, 
MDA231 e MCF7, ho potuto dimostrare che le proteine p63 e 
YB-1 interagiscono. Tale interazione è stata verificata sia per 
proteine espresse in maniera endogena sia per proteine 
esogene  espresse in maniera transiente mediante trasfezione. 
Ho potuto inoltre mettere in evidenza che la proteina YB-1 
interagisce specificamente con le isoforme ma non  di p63 
svelando quindi l’importanza della regione carbossi-terminale -
specifica di p63 nell’interazione con YB-1. Al fine di stabilire se 
l’interazione dimostrata fosse diretta, i cDNA codificanti le 
proteine Np63  Np63 e YB-1 sono stati sub-clonati in 
vettori per l’espressione in E.coli. Le proteine sono state 
espresse e purificate per cromatografia di affinità ed utilizzate in 
esperimenti di Far-western. Tale saggio ha confermato, in vitro, 
che YB-1 interagisce specificamente con l’ isoforma Np63 e 
non con la  e che tale interazione è appunto diretta.  
II. E’ stata, quindi, analizzata la capacità delle diverse isoforme di  
p63 di influenzare i livelli di espressione di YB-1, e viceversa. 
Come osservato, p63 e YB-1 non esercitano alcun controllo 
reciproco sulla loro espressione genica. Ciò è stato dimostrato 
sia a livello di mRNA mediante l’approccio della Real Time PCR 
sia a livello di proteina mediante esperimenti di silencing o di 
iper-espressione transiente. Tuttavia, l’analisi della emivita della 
proteina YB-1 ho potuto mettere in evidenza che essa è di gran 
lunga superiore in cellule che esprimono Np63 rispetto a 
cellule che ne sono prive.  Ciò è vero sia nel caso in cui la 
proteina Np63 sia endogenamente espressa, sia nei casi in 
cui la proteina venga espressa in seguito a trasfezione. YB-1 è 
un fattore pleiotropico coinvolto in numerosi processi cellulari 
che vanno dal controllo della trascrizione al controllo della 
traduzione di specifici messaggeri. Sebbene in condizioni 
normali YB-1 sia localizzata prevalentemente nel citoplasma, 
essa è in grado di traslocare dal citoplasma al nucleo e 
viceversa. Dal momento che p63 è un fattore trascrizionale 
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localizzato prevalentemente in sede nucleare, mi sono chiesto 
quale fosse la localizzazione di YB1 in presenza di Np63. 
Per  rispondere a tale quesito ho analizzato la localizzazione 
sub-cellulare di YB1, in assenza ed in presenza di p63, 
mediante fluorescenza diretta e l’uso della proteina YB-1 fusa 
all’epitopo GFP. Parallelamente ho svolto saggi di 
localizzazione cellulare mediante immunofluorescenza sulla 
proteina YB-1 endogenamente espressa. Tali esperimenti sono 
stati condotti in cellule derivate da cancro del seno dove 
l’iperespressione di YB-1 è nota indurre un fenotipo tumorale 
aggressivo. Ho potuto osservare che Np63 è in grado di 
determinare accumulo di YB-1 in sede nucleare. Il dato è stato 
confermato anche mediante la messa a punto di un protocollo 
per la separazione differenziale in gradiente di saccarosio degli 
estratti citoplasmatici e nucleari. Mediante questo approccio ho 
potuto notare che l’espressione dell’isoforma Np63 causa 
attivazione della chinasi pAkt. Questo aspetto è particolarmente 
interessante in quanto il pathway di PI3K/Akt(PKB) è noto 
giocare un ruolo chiave nella genesi e progressione di molte 
forme tumorali. YB-1 è un noto target della chinasi Akt che lo 
fosforila sulla serina in posizione 102. Tale evento di 
fosforilazione determinerebbe una modifica conformazionale di 
YB-1, cui fa seguito il suo distacco dagli mRNA citoplasmatici e 
la sua traslocazione nucleare. Dal momento che Np63 
induce attivazione di Akt era ragionevole presupporre che 
l’accumulo nucleare di YB-1, mediato da p63, potesse 
dipendere dall’attivazione della chinasi Akt. Questo aspetto è 
stato affrontato mediante due diversi approcci: 
i) Iper-espressione del mutante costitutivamente attivo di Akt.  
ii) Utilizzo del mutante fosfo-mimetico (S102D) e  del mutante 
fosfo-difettivo (S102A) di YB1. I risultati indicano che 
l’attivazione di Akt non è sufficiente a promuovere la 
traslocazione nucleare di YB-1 e che la presenza fisica di 
Np63 è necessaria e sufficiente a promuovere anche 
l’accumulo del mutante di YB1 non fosforilabile da Akt.  
III.  Come precedentemente accennato, YB-1 opera nel nucleo 
come fattore trascrizionale. Un noto target di YB-1 è il gene 
PI3KCA, codificante la sub-unità catalitica dello fosfotidil-
inositolo-3-chinasi. Attraverso la tecnica della immuno- 
precipitazione della Cromatina (ChIP) abbiamo dimostrato che 
in presenza di Np63 aumenta il legame di YB-1 al promotore 
del gene PI3KCA. Inaspettatamente, abbiamo osservato che la 
stessa proteina Np63 è in grado di legare il promotore 
PI3KCA. Mediante saggi reporter (luciferasi) abbiamo 
dimostrato che Np63 è un attivatore trascrizionale di PI3KCA 
e che il silenziamento di YB-1 riduce l’attività di p63 su questo 
promotore. Questo dato indica che YB-1 e p63 cooperano nella 
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regolazione dell’espressione della proteina PI3KCA. Per quanto 
concerne le attività citoplasmatiche, è noto che YB1 promuova 
la traduzione cap-indipendente dei  trascritti di Snail1 e Twist, 
due fattori coinvolti nella transizione epitelio-mesenchima 
(EMT). Mediante saggi di immunoprecipitazione dell’ RNA con 
anticorpi diretti contro YB-1 ho potuto osservare una riduzione 
della quantità di YB-1 legata al trascritto di Snail1, in cellule 
esprimenti p63. Un risultato analogo è stato ottenuto sul 
trascritto di YB-1, sul quale si lega la stessa proteina YB-1. 
Coerente con quanto osservato negli esperimenti di RNA-IP, i 
livelli di proteina Snail 1 appaiono ridotti e si verifica un 
aumento della E-caderina in presenza di Np63, la riduzione 
di Snail non riguarda il trascritto la cui abbondanza, misurata 
mediante esperimenti di rt-PCR, risulta invariata. Per contro ho 
potuto costatare una diminuzione del trascritto di Twist in 
presenza di Np63 Al fine, dunque, di dimostrare se quanto 
osservato a livello molecolare avesse un effetto in termini di 
mobilità cellulare abbiamo condotto saggi di migrazione con 
microscopia ―single cell tracking‖ utilizzando cellule H1299 
Np63 Tet-on, in cui cioè l’espressione di Np63 è inducibile 
mediante aggiunta di doxiciclina nel mezzo di coltura. In 
collaborazione con il gruppo del Prof. Netti abbiamo eseguito 
misure di velocità di migrazione e persistenza cellulare. 
Quest’ultimo parametro esprime il tempo in cui una cellula 
migra in una stessa direzione. Le cellule H1299/Np63 TET-
on sono state trasfettate con il vettore codificante la proteina 
YB1-GFP. Un numero statisticamente significativo di cellule 
fluorescenti è stato seguito in ―Time lapse‖ per misurarne la 
velocità di migrazione e la persistenza. Le cellule iper-
esprimenti YB-1 presentavano un incremento della velocità 
media di migrazione pari ad un fattore di 1.3 ed una riduzione di 
persistenza pari al 40% del controllo (cellule trasfettate con il 
vettore esprimente la sola GFP). Per contro, le cellule 
esprimenti YB1-GFP e Np63+dox) si comportano in 
maniera quasi sovrapponibile al controllo, indicando che p63 è 
in grado di revertire il fenotipo indotto dalla iper-espressione di 
YB1. Infine, grazie ad una collaborazione con il Dott. Enzo Di 
Iorio della Banca degli occhi Veneta, abbiamo esaminato 
l’espressione di YB-1 e Np63 nell’epitelio corneale a riposo 
ed in fase rigenerativa (dopo una lesione) mediante tecniche di 
immunoistochimica. Abbiamo osservato la localizzazione 
prevalentemente nucleare per p63 e quella citoplasmatica per 
YB-1. Peraltro, è frequente la sovrapposizione dei segnali di 
YB-1 e p63  particolarmente in quelle cellule che si spostano 
dallo strato basale dell’epitelio corneale a quello sovrastante 
dove perdendo le caratteristiche staminali si avviano al 
differenziamento terminale. Ulteriori studi saranno necessari 
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per comprendere a fondo il ruolo dell’associazione di p63 e YB1 
nella rigenerazione di tale tessuto. In conclusione, durante il 
mio lavoro di dottorato, ho dimostrato l’esistenza di un 
complesso ΔNp63α/YB-1 in grado di esercitare un’attività di 
controllo sia sul pathway di PI3K/Akt sia su geni che attivano la 
transizione epitelio-mesenchima. Ambedue questi pathway 
sono coinvolti nel processo di tumorigenesi e progressione 
tumorale. Il mio lavoro getta le premesse per uno studio volto 
ad identificare nuove molecole e strategie terapeutiche per 
contrastare il processo tumorale. 
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Abstract 
Scientific and Methodological premises  
 
The p63 (TP63/TP73L) gene, a homologue of the tumor-
suppressor p53, is the founder member of the p53 gene family 
(Yang A. et al., 1998; M. Osada et al., 1998). Using two 
different promoters and alternative splicing events at the C-
terminal end, the p63 locus gives rise to a total of six protein 
isoforms. Among them, three exhibit an N-terminal 
transcriptional activation domain (TA) and are functionally 
similar to p53 (TAp63  and ) while the remaining lack the 
TA domain and are able to promote survival and cell 
proliferation ( Np63     and   (Schmale et al., 1997). 
TAp63 is most similar to p53, while the  isoforms  possess a 
considerable extension to the C-terminus including a conserved 
protein-protein interaction domain known as "Sterile Alpha 
Motif" (SAM). The analysis of knockout mice demonstrates 
unequivocally that p63 exerts a crucial role in the development 
of epithelial tissues including the skin and organs derived from 
epithelial-mesenchymal interactions such as salivary glands, 
lacrimal, mammary and prostate (Yang A. et al., 1999). Np63 
actively guides the early stages of development and governs 
the fate of the epidermal basal layer (Romano et al., 2009). In 
adult epidermis, the basal layer contains proliferating 
keratinocytes that express high levels of Np63. Deregulated 
expression of Np63 was found to be closely associated with 
skin cancer in humans (Parsa et al., 1999). However, the role 
that Np63 plays in cancer development and progression, with 
particular regard to the metastasis process, is quite 
controversial. For example, the absence of the expression 
Np63 is characteristic of anaplastic tumors of the bladder, 
ureter and breast cancer (Urist MJ et al. 2002; F. Koga et al. 
2003; X. Wang et al., 2002) and the over- expression of mutant 
splicing Np63 has been observed in many metastatic 
squamous cell carcinomas (Westfall and Pietenpol 2004). 
Furthermore, in squamous cell carcinoma, the Snail1 
transcription factor that promotes epithelial-mesenchymal 
transition (EMT), represses Np63 thus favoring tumor 
metastasis (Herf et al. 2010).  
The functional activity of each protein is linked to its interactions 
with other molecules and, in eukaryotic cells, at his location in 
the correct sub-cellular compartment. In fact, only in the right 
compartment a protein will make interaction with the correct 
"partners".  
In the lab where I did my thesis, a functional proteomic 
approach was undertaken to clarify the role played Np63 in 
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cancer pathogenesis and progression. Understanding the 
mechanisms by which p63 controls the genesis and 
progression of tumors as well as the pathogenesis of 
ectodermal dysplasias will represent a milestone for 
development of new drugs and therapeutic strategies.  
The YB-1 oncoprotein was identified among the potential 
Np63 interactors.  YB-1 is an important tumor marker for 
breast cancer, lungcarcinoma, adenocarcinoma, osteosarcoma, 
colorectal cancer and melanoma (Wu et al. 2007).  
The goal of my work was to understand the functional role of 
the association between Np63 and YB-1. YB-1 was already 
known to functionally interact and translocate with p53 to the 
nucleus to regulate p53-dependent gene expression. YB-1 
controls the transcription and translation of many factors 
"shuttling" between the nucleus and cytoplasm. Into the 
nucleus, YB-1 regulates the transcription of genes involved in 
chemo-resistance, directly or through the association with p53, 
AP-1, Smad3 or p300 (Bader 2005), and pro-proliferative genes 
such as cyclin A, cyclin B1, DNA pol and PI3KCA, the 
phosphatidylinositol-3-kinase catalytic subunit (PI3K) (Jurchott 
2003, En-Nia, 2005; Astaneh 2009). In the cytoplasm, YB-1 
plays a more structural role being involved in the spatial 
organization of mRNPs (Skabkin, M. A 2004). In particular, 
binding to Cap 5 'transcripts compete with eIF4E and eIF4G 
translation initiation factors blocking translation of specific 
mRNA. On the other hand, YB-1 can bind and activate cap-
independent translation of specific messenger RNAs, such as 
that of SNAIL1, a factor involved in EMT (epithelial-
mesenchymal transition) that blocks the expression of E-
cadherin (Battle et at., 2000).  
In breast cancer, YB-1 protein expression levels are correlated 
with reduced E-cadherin expression and a poor prognosis 
(Evdokimova, 2009). In addition, the YB-1 over-expression in 
non-invasive breast cancer cell lines induces epithelial-
mesenchymal transition (EMT) accompanied by increased of 
metastatic potential and a reduced proliferation level 
(Mouneimme G., 2009).  
My research is thus divided into the following four phases: 
I. Study of the interaction between the p63 isoforms and YB-1 
using in vitro approaches, in different cell contexts (Saos2, 
U2OS, H1299, HaCaT, Hela, MCF7, and MDA231).  
II. Determination of the mutual effect on protein expression 
levels and stability. Analysis of sub-cellular localization through 
immuno-localization and fluorescence microscopy. Measures of 
"protein-decay" in cells treated with inhibitors of protein 
synthesis. 
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III. Analysis of the effect of the interaction with p63 on some 
YB-1 nuclear and cytoplasmic functions by chromatin and RNA 
immunoprecipitation, real-time PCR techniques and luciferase 
assays. 
IV. Determination of the effect of p63 and YB-1 interaction on 
proliferation and cell migration. Analysis of expression in 
primary keratinocytes and intact or regenerating corneal 
epithelium.  
 
Results 
 
Through co-immunoprecipitation assays, performed in different 
cell lines such as Saos2, U2OS, H1299, HaCaT, Hela, MCF7, 
and MDA231, I demonstrated that p63 and YB-1 proteins 
interact. This interaction was verified on both endogenous and 
exogenously expressed proteins. Moreover, I have shown that 
the YB-1 protein specifically interacts with  but not  p63 
isoforms thus revealing the importance of the p63 -specific 
carboxy-terminal in the YB-1 interaction.  
In order to establish that the interaction was direct, I subcloned 
cDNAs encoding Np63, Np63 and YB-1 proteins into E. 
coli expression vectors. The proteins were expressed and 
purified by affinity chromatography and used in Far-western 
experiments. This assay confirmed, in vitro, that YB-1 interacts 
specifically with Np63  but not  isoform and that this 
interaction is direct.  
I analyzed the ability of different p63 isoforms to influence the 
YB-1expression levels, and vice versa. It has to be noted that 
p63 and YB-1 have no control over their mutual gene 
expression. This has been demonstrated both at mRNA and 
protein level by silencing experiments or transient over-
expression.  
However, I have found that YB-1 protein half-life is much higher 
in Np63 expressing cells compared to cells lacking p63 
expression. This is true in cells expressing endogenous 
Np63 as well as in those overexpressing exogenous p63.  
YB-1 is a pleiotropic factor involved in many cellular processes 
including the control of transcription and translation. Although 
under normal conditions YB-1 is mainly localized in the 
cytoplasm, it is able to move from the cytoplasm to the nucleus 
and vice versa. Since p63 is a transcription factor localized 
predominantly in the nuclear, I wondered what was the 
localization of YB1 in presence of Np63. To answer this 
question I analyzed the YB1 sub-cellular localization, in the 
absence and presence of p63, by direct fluorescence and the 
use of YB-1/GFP protein. In parallel I've done cellular 
localization by immunofluorescence assays on the 
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endogenously expressed YB-1 protein. These experiments 
were conducted in cells derived from breast cancer, where YB-
1 overexpression is known to induce a tumor aggressive 
phenotype. I have shown that Np63 is able to determine YB-
1 accumulation in the nuclear compartment. This was also 
confirmed by the development of a protocol for differential 
separation in sucrose gradient of cytoplasmic and nuclear 
extracts. With this approach I have observed that Np63 
expression causes Akt kinase activation. This is an intriguing 
point since the PI3K/Akt pathway (PKB) is known to play a key 
role in the genesis and progression of many cancers.  
YB-1 is a well known target of Akt kinase. Phosphorylation of 
Ser102 of YB-1 is supposed to cause a conformational change 
of YB-1 followed by its detachment from cytoplasmic mRNA 
and nuclear translocation. Since Np63 induced Akt activation 
I assumed that YB-1 nuclear accumulation was dependent on 
Akt kinase activation. I addressed this aspect with two different 
approaches:  
i) Analysis of the effect of constitutively active Akt mutant on YB1 
subcellular localization. 
ii) Analysis of the effect of Np63 expression on the subcellular 
localization of the YB1 phospho-mimetic (S102D) or phospho-
defective (S102A) mutants.  
The obtained results indicate that Akt activation is not sufficient 
to promote YB-1 nuclear translocation and that Np63 is 
necessary and sufficient to promote the nuclear accumulation of 
YB1.  
As previously mentioned, YB-1 operates in the nucleus as a 
transcription factor. A well-known target of YB-1 is the PI3KCA 
gene, encoding the catalytic subunit of fosfotidil-inositol-3-
kinase. Through Chromatin Immuno-Precipitation (ChIP) I have 
demonstrated that Np63 increases the binding of YB-1 to 
PI3KCA gene promoter. Surprisingly, I have observed that the 
same Np63 protein is able to bind the PI3KCA promoter. 
Using reporter assays (luciferase) we have shown that Np63  
is a PI3KCA transcriptional activator and YB-1 silencing 
reduces the p63 activity on this promoter. This data indicates 
that YB-1 and p63 cooperate in the control of PI3KCA gene 
expression.  
Concerning the cytoplasmic activities, it is known that YB1 
promotes cap-independent translation of Snail1 and Twist 
transcripts, two factors involved in epithelial-mesenchymal 
transition (EMT). By RNA immunoprecipitation assays with YB-
1 antibodies I have seen a reduction in the amount of YB1-
bound Snail1 transcript, in p63 expressing cells. A similar result 
was obtained on the YB-1 transcript, which is bound by YB-1 
protein. Consistent with this, by western blot experiments, I 
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observed that, in presence of Np63, Snail 1 protein was 
reduced while E-cadherin was increase.  
By inducing pro-metastatic genes YB-1 increases cell motility. 
To analyse the effect of Np63 on cell motility I have carried 
cell migration assays with "single-cell tracking time-lapse 
microscopy‖ using H1299 Np63 Tet-on cells, in which the 
expression of Np63 is inducible by doxycycline.  
In collaboration with the Prof. Netti group we performed 
measurements of cell migration speed and persistence. H1299 
Np63 TET-on cells were transfected with the YB1/GFP 
encoding vector. A statistically significant number of fluorescent 
cells was followed in "Time Lapse" to measure the migration 
speed and persistence. The YB-1 over-expressing cells showed 
an increase in average speed of migration by a factor of 1.3 and 
a reduction in the persistence of 40% of control (cells 
transfected with the GFP expressing vector). In contrast, GFP-
YB1 and Np63 + dox) expressing cells behave almost 
comparable to the control. The obtained results indicate that 
p63 is able to reverse the motility phenotype induced by YB1 
over-expression. Finally, thanks to a collaboration with Dr. Enzo 
Di Iorio of Eye Bank of Veneto, we examined the YB-1 and 
Np63 expression in intact and regenerative (after an injury) 
corneal epithelium by immunohistochemistry. We observed the 
predominant p63 nuclear and YB-1 cytoplasmic localization. 
However, we have observed a frequent overlapping between 
YB-1 and p63 signals, particularly in those cells that move from 
the basal to the suprabasal layer of the corneal epithelium, 
where they lose the stem cell features and initiate terminal 
differentiation. Further studies will be needed to fully 
understand the role of the p63 and YB1 association in the 
regeneration of this tissue.  
In conclusion, during my PhD work, I provided evidences of a 
ΔNp63α/YB-1 complex able to interfere with the PI3K/Akt 
signalling pathway. I also proved that Np63 can affect the 
ability of YB-1 to support the epithelial-mesenchymal transition. 
Therefore, my work provides additional knowledge on pathways 
that are crucial for tumor development and lays the premises for 
the study of new molecules and therapeutic strategies to 
counteract tumor pathogenesis and/or progression. 
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Abbreviations 
 
AEC Ankiloblpharon-ectodermal dysplasia–clefting  
ChIP Chromatin ImmunoPrecipitation  
CSD Cold-Shock Domain 
DBD DNA-binding domain  
ED Ectodermal Dysplasia 
EEC Ectrodactyly-ectodermal dysplasia–clefting syndrome  
eIF eukaryotic Initiation Factor  
EMT Epithelial-Mesenchymal Transition 
GBM Glioblastoma Multiforme  
GFP Green Fluorescent Protein 
HNSCC Head and Neck Squamous Cell Carcinoma 
LMS Limb mammary syndrome  
OD Oligomerization domain  
PIK3CA Phosphoinositide-3-kinase Catalytic Alpha polypeptide. 
RNP Ribonucleoprotein 
SAM Sterile Alpha Motif  
SCC Squamous Cell Carcinomas  
SHFM Split Hand Split Foot malformation  
siRNA small interfering RNA 
TA Transactivation domain 
TGF Tumour Growth Factor 
TID Transactivation inhibitory domain 
YB-1 Y Box Binding protein 1 
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Introduction 
 
 
1.1 The p63 gene discovery  
 
The p53 tumor suppressor gene that plays an unprecedented 
role in human cancer was, for a long time, thought to be unique 
(in structure and function) until the discovery of two additional 
members of this protein family: p73 in 1997 [Kaghad, M et 
al.1997] and p63 in 1998 [Yang, A.N. et al. 1998]. p63 and p73 
were discovered by virtue of their homology with the p53 
oncosuppressor, thus it was natural for researchers and 
clinicians to consider these newly discovered p53-like genes as 
tumor suppressors. Like p53, p63 and p73 use alternative 
promoters and multiple splicing events to generate an array of 
functionally and structurally distinct isoforms.  
Phylogenetic analysis indicated that p63 and p73 are 
evolutionary older than p53, and it was suggested that p63 may 
be the evolutionary predecessor of both p53 and p73 [Yang, 
A.N. et al. 1998, Joerger, A.C. et al. 2009]. Non vertebrate 
animals have only one gene of the p53 family, and it has a high 
degree of similarity to vertebrate Np63 [Stifanic, M et al. 2009]. 
Interestingly, while the evolutionarily older family members, p63 
and p73, play crucial but different roles in mammalian 
ontogenesis, p53 is specifically responsible for tumor 
suppression. However, p53, p63 and p73 share a common 
protein structure, which arises from their function as 
transcription factors. They consist of a central DNA-binding 
domain (DBD), a transactivation (TA) domain, and an 
oligomerization domain (OD). Furthermore, all three act as 
tetramers, and partial homology in the OD results in their 
potential ability to form heterotetramers. The central DBD 
domain of p63 is highly homologous with the DBDs of p53 and 
especially p73, suggesting that the three members of the p53 
protein family can potentially share the ability to transactivate a 
common set of target genes [Yang, A.N. et al. 1998]. However, 
increasing evidences indicate that each homolog can exhibits 
specificity for the control of a particular set of genes [Dohn, M. 
et al. 2001 - Vigano, M.A et al. 2006]. 
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1.1.2 TP63 gene and the p63 protein isoforms 
 
The human TP63 gene maps on chromosome 3q28 and it 
consists of 15 exons and two alternative promoters (Fig. 1) 
(Yang, A. et al., 1998).  
P63 protein isoforms include full-length isoforms having a 
transactivation (TA-) domain homologous to that of full-length 
p53, and amino-terminally truncated (N-) isoforms. Alternative 
promoter usage and multiple splicing events contributes to the 
enormous complexity of p63 gene expression (Fig. 1) [Mangiulli 
et al., 2009].Transcription from the first promoter, located 
upstream of exon 1, gives rise to the full-length protein TAp63. 
Transcription from the second promoter results in the 
production of N-terminally truncated protein isoforms, ΔNp63. 
Alternative splicing, at the 3’ end of TP63 mRNA generates 
distinct C-terminal protein isoforms that are known as α, β, γ 
and the newly described δ and ε.  
The TA and ΔNp63α protein isoforms contain a conserved 
Sterile Alpha Motif (SAM), also present in proteins controlling 
development and cell differentiation processes. The SAM 
domain is known to be responsible for protein-protein 
interactions [Thanos, C.D. and Bowie,  1999]. Alpha isoforms 
also have a C-terminal transactivation inhibitory domain (TID). 
The TID domain is able to physically bind and negatively 
regulate TAp63 transcriptional activity through an 
intramolecular inhibitory mechanism [Ghioni et al. 2002, Helton 
et al. 2006]. Accordingly, the splicing isoforms lacking this 
region () have stronger transactivation potential. 
Interestingly, The TID domain is known to be removed by 
activated caspases following pro-apoptotic stimuli [Sayan et al. 
2007]. [Serber et al. 2002].  
ΔNp63 isoforms that do not contain the N-terminal TA domain 
act as dominant negative of TAp63 isoforms and other 
transcriptionally active members of the p53 family (TAp73 and 
p53), partly due to its competition for binding to promoters of 
the target genes and partly due to the formation of non-
functional hetero-oligomers. According to this model, the 
balance between the TA and N isotypes, and the splicing 
isoforms (lacking the TI) can finely regulate p63 functional 
activity.  
The observation that Np63 enforced expression is able to 
transactivate p53 responsive genes and induce cell-cycle arrest 
and apoptosis was truly unexpected [Dohn, M. et al. 2001]. 
However, more recently, a second TA domain (TA2), located 
downstream the DNA binding domain, has been identified and 
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described to confer an intrinsic transcriptional activity to Np63 
isoforms [Ghioni et al. 2002]. 
 
 
 
 
Figura 1: Transcription from the upstream promoter, P1, generates TAp63 isoforms that 
contain a TA domain homologous to that of full-length p53 (red). Transcription from the internal 
promoter, P2, generates the N-terminally truncated isoform class Np63. Although Np63 is 
devoid of the p53-like TA domain present in the TAp63 isoforms these proteins have a unique 
TA domain (red hatched bars) encoded by exon 30. Alternative splicing of C-terminal exons 
generates a isoforms containing a sterile alpha motif (SAM domain, blue) followed by a 
transcriptional inhibitory domain (TID).  and isoforms have unique C-termini (orange and 
yellow, respectively). Abbreviations: DBD, DNA binding domain (green); NLS, nuclear 
localization sequence; P, proline-rich domain; OD, oligomerization domain.  
 
1.1.3 Functional role of p63 in the control of cell 
proliferation transformation and death. 
 
The p63 gene encodes for products displaying similar or 
antagonistic activities. For instance TAp63 isoforms, and 
particularly the gamma isoform, are similar to p53 with regards 
to its ability to modulate genes that mediate cell cycle arrest 
and apoptosis— including BAX, p21, PUMA (p53-upregulated 
modulator of apoptosis).  
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On the other hand, consistent with its proposed oncogenic role, 
Np63 was shown to repress the pro-apoptotic gene IGFBP-3 
and transactivate HSP70, an anti-apoptotic stress-response 
protein associated with cell malignancy and transformation that 
play protective roles against cell death induced by a variety of 
insults – an observation that contrasts with the ability of Np63 
to induce apoptosis [Wu G. et al. 2005]. [Barbieri et al. 2005]. 
Np63 can be degraded by p53 upon DNA damage, resulting in 
p53-dependent activation of glycogen synthase kinase (GSK)-
3b followed by b-catenin degradation [Ratovistski, E. et al. 
2001]. However, in epidermal cancers, Np63 is not degraded 
by mutant p53, and is free to bind to the B56 subunit of protein 
phosphatase 2A and alter its conformation. This results in a 
dramatic inhibition of GSK3 with dismantling of the APC 
complex: the non-phosphorylated -catenin aberrantly 
accumulates in the nucleus, resulting in the activation of T-cell 
factor and lymphocyte enhancer binding factor responsive 
elements, which contributes to tumourigenesis [Patturajan, M. 
et al. 2002]. 
Because of the ability of p63 to bind p53-like consensus sites, 
several attempts have been made to characterize p63 specific 
target genes. For instance, p63 has been shown to activate 
many – but not all – p53 responsive genes, such as p21, Bax 
and mdm2, although less efficiently. By microarray analysis, it 
was identified a set of genes selectively activated following 
infection of Saos2 cells with recombinant adenoviruses 
expressing TAp63 and Np63 [Wu, G. et al. 2003]. Not 
unexpectedly, genes modulated by both TAp63 and Np63 
include those involved in cell-cycle control, cell signalling, 
proliferation and apoptosis, and epidermal differentiation. Again, 
many of those genes induced by TAp63 were also p53-
responsive, such as p21, c-fos and IGFBP-3. However, TAp63a 
failed to activate many p53-responsive targets and also 
influenced the expression of many genes unaffected by p53. 
This suggests that p53 and TAp63 isoforms have overlapping 
but distinct functions within the cells.  
TAp63 was shown induce apoptosis through two distinct 
mechanisms: (1) activation of death receptors and (2) the 
mitochondrial pathway. Actually, TAp63 can trigger the 
expression of CD95 , TNF-R and TRAIL-R death receptors. 
Furthermore, TAp63 upregulates the expression of 
proapoptotic Bcl-2 family members like Bax and BCL2L11 and 
the expression of RAD9, DAP3 and APAF1. Of clinical 
relevance is the fact that TAp63 is induced by many 
chemotherapeutic drugs and that inhibiting TAp63 function 
leads to chemoresistance [Gressner O et al. 2005].  On the 
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other hand, in p53 null human breast cancer cells, unlike 
TAp73, TAp63 cannot functionally replace p53 in adriamycin-
induced cell cycle arrest and apoptosis thus raising some 
reasonable doubts on  the relevance of p63 as a pro-apoptotic 
gene [Vayssade M, et al. 2005].  
Flores ER and collaborators [Nature 2002] demonstrate that 
p63 is required for p53-mediated apoptosis in E1A-expressing 
mouse embryonic fibroblasts; whether this effect is specifically 
due to E1A expression, or not, still needs to be clarified. 
Nonetheless, it was demonstrated that p63 was required for 
radiation-induced p53-mediated apoptosis in developing 
nervous system, a more physiological setting. Finally, an in vivo 
study demonstrated that p63 is dispensable for both p53-
dependent and p53-independent apoptosis in T-cells, in 
response to both gamma irradiation and receptor-mediated T-
cell activation [Senoo M et al 2004; Benchimol S 2004 ]. All 
together, the available experimental evidences seem to indicate 
that p63 can potentially play a pro-apoptotic role but  the 
relevance of p63 activity in the induction and control of 
apoptosis depend on the particular stimuli and cell contexts.  
 
 
1.1.4 Role of p63 in Skin and Epithelial 
Development 
 
The central role of p63 in epidermal development became 
established with the publication of the two independent studies 
on p63 -/- mouse models, generated by disrupting exons 
common to both TA and N isoforms [Yang et al. 1999; Mills et 
al. 1999]. Both mice were born alive, but died within hours after 
birth because they fail to develop skin.  
The p53 knock-out mice exhibited high incidence of tumors but 
no developmental abnormalities. Two independent groups 
generated p63-deficient mouse models, and these mice had 
severe developmental abnormalities that precluded the analysis 
on whether germ line p63-knockout causes a tumor-prone 
phenotype [Yang A, et al. ; Mills et al. 1999].  
Given that also p53+/- heterozygous mice develop highly 
penetrant tumors, although with a delayed onset in comparison 
with that of p53 null mice, it seemed straightforward to ask 
whether p63+/- mice were also tumor prone.  
Flores and collaborators [Flores ER, et al. 2005] reported that, 
although they did not display a highly penetrant tumor 
phenotype, p63+/- mice were prone to tumor development more 
than the wild type mice and in their tumor cells the wild type p63 
allele was lost.They also observed that p63 heterozygosity in a 
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p53-compromised background increased tumor burden and 
enhances metastasis, supporting the hypothesis that p63 
cooperates with p53 in tumor suppression, in vivo.  
An independent study by Alea Mills and MW Keyes reached 
exactly the opposite conclusion showing that p63+/- mice are 
not prone to either spontaneous or chemically induced tumors. 
In addition, they found that p63 heterozygosity effectively 
reduced spontaneous tumor incidence in p53-compromised 
mice, indicating not only that p63 is not working as a tumor 
suppressor but that reduced dosage of p63 might even be 
protective against tumor [A. Mills et al. 1999]. This hypothesis is 
also supported by the observation that p63 deficiency in adult 
mice activates a program of cellular senescence [Keyes WM et 
al. 2005] an irreversible, cell cycle arrest that effectively halts 
aberrantly proliferating cells [Sharpless NE,  DePinho RA 2005]. 
The take-home message of the Flores study [Flores ER, et al. 
2005] is that p63 functions as a tumor suppressor, and that 
combined loss of p63 and p53 cooperates in malignancy, 
whereas the Keyes study concludes that p63 does not function 
as a tumor suppressor and supports the hypothesis that 
reduced p63 decreases the tumor-prone phenotype of p53-
compromised mice [WM Keyes and AA Mills, unpublished]. The 
different conclusions might result from the fact that the two 
studies used mice heterozygous for distinct p63 alleles, one of 
which retains the reading frame in the targeted allele[Yang A, et 
al. ; Mills et al. 1999]. Indeed, initial reports of the  phenotypes 
caused by p63 deficiency led to different models for the role of 
p63 in skin morphogenesis [McKeon F 2004]. Do these different 
conclusions, which were based primarily on the presence or 
absence of epidermal markers of differentiation, reveal genetic 
differences between the distinct p63 alleles? The answer to this 
question might be also important for determining whether the 
two targeted p63 alleles function similarly in tumorigenesis. 
The idea that reduced levels of p63 might protect the cell from 
malignancy is intriguing and in agreement with the supposed 
pro-proliferative role for p63. However, it appears quite clear 
that p63 and p53 are not equivalent in their ability to suppress 
uncontrolled cell proliferation although further experiments 
should be done to shed light on this controversial aspect of p63 
biology.  
Np63 isoforms in the adult are strongly expressed in epithelial 
cells with high clonogenic and proliferative capacity, and p63-/- 
epithelial stem cells undergo premature proliferation rundown, 
both in epidermis and thymus, indicating that p63 is a key 
determinant of the proliferative capacity of epithelial stem cells 
[Senoo et al. 2007].  
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Two hypotheses for the role of p63 in epidermal development 
were proposed based on the phenotype of p63-/- mice, which 
are born with a single-layered surface epithelium instead of a 
fully stratified epidermis. In the first model, one round of 
epidermal stratification is predicted to occur, however, the 
epidermis would not be maintained due to a premature 
depletion of epidermal stem cells [Yang et al., 1999]. If this 
hypothesis is correct the epithelium would be expected to 
express K5 and K14. An alternative explanation is that p63 is 
involved in the commitment to stratification. In this model, 
epidermal stratification never initiate, therefore one would 
predict that this epithelium express K18, but not K5 and K14 
[Mills et al., 1999]. Notably, the second hypothesis turned to be 
true as p63 null surface epithelial cells do not express K5 and 
K14, instead they express K18, a marker for the uncommitted 
surface ectoderm. 
Additional evidences that p63 drives epidermal development 
were obtained by genetic complementation. By crossing 
TAp63 or Np63epidermal transgenic mice into p63-/- mice, 
Candi et al. generated animals expressing only one isoform 
under the K5 promoter to identify the relative contribution of 
each variant to the development of the epidermis and thymus 
[Candi et al. 2006; Candi et al. 2007]. Although they  were 
unable to obtain a full reversion of the p63 null phenotype, the 
Np63 complemented transgenic mice (p63-/-;N) developed a 
significant epidermal basal layer, while those complemented 
with TAp63 (p63-/-;TA) are very similar to p63-/- mice. Double 
complemented mice, however, exhibited a greater degree of re-
epithelialization with expression of keratins of the basal layer 
(K5 and K14) and later differentiation markers such as K1 and 
loricrin; however, complete cornification remained impaired 
[Candi et al 2006]. These data suggested that Np63 is 
important for maintaining the proliferative potential of the basal 
layer, whereas TAp63 contributes to epidermal differentiation by 
acting synergistically with and/or subsequently to Np63.  
A study based on RNA interference directed against specific 
p63 isoforms, demonstrated that Np63 isoforms are the main 
mediators of p63 effects while TAp63 isoforms contribute to 
later stages of differentiation, in mature keratinocytes. In this 
work, the roles of p63 in differentiation and cell proliferation 
were shown to be distinct. Indeed, downregulation of p63, in 
keratinocytes, causes a p53-dependent cell cycle arrest while 
simultaneous knockdown of p53 in the context of p63 loss is 
able to rescue cell proliferation but not the differentiation defect 
[Lee et al., 2002; Truong et al. 2006].  
To get insights into the p63 functions, several approaches have 
been taken, over the last few years, to identify its target genes 
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These studies provided clear evidences that p63 controls and 
connects different pathways involving cell differentiation, 
adhesion and proliferation [Pozzi et al. 2009]. 
Though the original controversy on Np63 being involved in 
stemness or differentiation has been solved, still the underlying 
molecular mechanisms involved await elucidation. Even though 
TAp63 expession is hard to detect in the epidermis, it seems to 
be induced under stress stimuli and during wound healing, 
indicating a role in tissue regeneration and cell death [Lin et al. 
2009].  
 
1.1.5 Human congenital diseases linked to p63 
disfunction.  
 
Given the role played by the p53-like proteins as master 
regulators of crucial developmental processes, the finding of 
pathological abnormalities linked to their dysfunction or 
imbalance, in humans, was expected. An extensive literature 
exists, supporting a crucial role for p63 in the pathogenesis of 
several human diseases. 
Germ line mutations of p63 are found in humans and are 
responsible for several rare autosomal dominant developmental 
diseases, such as the Ectrodactyly-ectodermal dysplasia–
clefting syndrome (EEC), the Ankiloblpharon-ectodermal 
dysplasia–clefting also known as Hay-Wells  syndrome (AEC), 
the Limb mammary syndrome (LMS), the ADULT syndrome, 
the Rapp-Hodgkin syndrome and non syndromic Split Hand 
Split Foot malformation (SHFM). ED is clinically characterized 
by malformation of skin, hair, nails and teeth, and by facial 
clefts. In addition, EEC patients show lachrymal duct 
abnormalities, urogenital problems, hearing loss, facial 
dismorphism, respiratory infections, and developmental 
retardation [Celli et al. 1999]. Most commonly, p63 mutations 
give rise to either amino acid substitutions in the DBD that 
abolish p63 DNA-binding ability or to shifts of the reading frame, 
which specifically truncate the -end region of p63 [Celli et al. 
1999]. AEC patients have mutations giving rise to amino acid 
substitutions in the SAM domain [McGrath et al. 2001]. These 
missense mutations are predicted to disrupt protein–protein 
interactions, by either destroying the compact globular structure 
of the SAM domain, or substituting amino acids, which are 
crucial for such interactions. Further interpretation of the 
biological consequences of the SAM domain mutations is 
obscured by our lack of knowledge of the physiological role of 
this structural domain. Mutated proteins have been shown to 
act as dominant negative molecules and, in fact, the disease 
occurs at heterozygous level. Mutations in the p63 carboxy-
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terminal-end cause SHFM. Several of these mutations lead to 
truncated forms of the protein that are shortened by eight 
(Q634X) or three (E639X) amino acids [Rinne et al. 2009]. 
These truncations remove a sumoylation site that seems to play 
an important role in the regulation of p63 [Ghioni et al. 2005; 
Huang et al. 2004; Straub et al. 2009].  
The pattern of mutations has revealed p63 protein domains that 
are particularly important for skin development (the carboxy 
terminal SAM domain), whereas other domains are crucially 
important for limb development (DBD, carboxy-terminal-end 
domain). A striking genotype/phenotype correlation can be 
easily recognized [Van Bokhoven and Brunner 2002; Rinne et 
al. 2006; Rinne et al. 2007]. The underlying molecular 
mechanisms leading to these diseases are under active 
investigation. 
 
1.1.6 p63 in cancer 
 
The p63 gene is a tumor suppressor, an oncogene or both? 
The answer still remains an open question. Several studies 
supporting the hypothesis that p63 can function as a tumor 
suppressor rely on the ability of full-length TAp63 isoforms to 
trigger cell cycle arrest and apoptosis [Yang et al. 1998; 
Gressner, O. et al. 2005]. On the other hand, ΔNp63α is known 
to inhibit both death receptor-mediated and chemotherapy-
induced apoptosis [Mundt, H.M., et al. 2010].  
Increasing evidences support the idea that ΔNp63 actually 
promotes cancer development thereby functioning as an 
oncogene. Squamous cell carcinomas of the lung or head and 
neck are characterized by amplification of the p63 locus as well 
as overexpression of ΔNp63α [Yamaguchi, K et al. 2000- 
Tonon, G et al. 2005]. Moreover, ΔNp63α enforced expression 
was shown to enhance cell growth in soft agar and increase 
tumor size in mice [Hibi, K. et al. 2000].  
However, the functional role of p63 isoforms in tumor 
pathogenesis and progression should not be studied without 
considering the effects due to other p53 family members. In fact 
it is still difficult to predict which might be the ultimate effect of 
hetero-tetramerization among p53-family members. For 
instance, even though the oligomerization domain (OD) of p53 
does not associate with the homologous domain of p63 or p73,  
p63 and p73 isoforms can assembly by forming hetero-
oligomers. ΔNp63 isoforms were described to affect the 
transactivation functions of TAp63, p53 and p73 via direct 
protein-protein interactions [Joerger, A.C et al. 2009].  
Multiple mechanisms have been described to explain how p53 
family members can regulate each-other’s activity: 
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(1) First, mutant p53 was demonstrated  to associate in vitro and in 
vivo with the p63 DNA binding domain and this interaction 
impairs the sequence-specific binding of p63. [Gaiddon, C et al. 
2001, Strano, S et al. 2002]. The inactivation of p63 by mutant 
p53 might be one of the possible mechanisms conferring 
mutant p53 gain of function.This mechanism seems to be 
operative in T47D cells expressing a mutant p53: in these cells 
p63 is unable to recruit some of its target gene promoters 
[Strano, S et al. 2002].  
(2) Secondly, the central domain of all p63 variants is highly 
homologous with the DBDs of p53 and p73, so that p63 can 
interact with the p53 consensus sites. TAp63 is able to 
transactivate reporter genes containing p53-responsive 
elements, while the ΔNp63 isoforms, lacking the N-terminal TA 
domain, can bind to p53 target sites in a competitive way and 
act as a dominant negative inhibitor of p53, TAp63 or TAp73. 
[Yang et al. 1998].  
(3) Thirdly, a cross regulation between p53 family members has 
been demonstrated. p63 associates with its own promoter as 
well as with the promoter of p53 and p73. Therefore, p63 may 
regulate its own level of expression as well as that of its 
relatives. Remarkably, ΔNp63 transcription is regulated by p53 
[Harmes, D.C. et al. 2003]. Disruption of p53 activity abolishes 
the expression of ΔNp63α.   This regulation is mediated by a 
p53-binding element sufficient to confer these activities to a 
heterologous promoter. Chromatin immune-precipitation 
indicates that, in asynchronously growing cells, p53 occupies 
this element. In response to DNA damage, Np63is recruited 
to this element as transcription of deltaN-p63 declines. 
Disruption of deltaN-p63expression had differential effects on 
the transcriptional regulation of several p53-target genes. 
These findings indicate that p53 contributes to the preservation 
of basal epithelia by driving the expression of deltaN-p63 
isoforms. Moreover, ΔNp63 is recruited to and can activate its 
own promoter, thus providing an autoregulatory loop of self-
regulation [Romano, R.A et al. 2006]. Importantly, loss of p53 
leads to the stabilization of TAp63γ [Li, N. et al. 2006]. 
Consequently, disruption of TAp63γ expression leads to 
decreased expression of ΔNp63, and overexpression of 
TAp63γ enhances the activity of the ΔNp63 promoter. Thus, 
TAp63γ is capable of activating the expression of ΔNp63. 
(4) Fourthly, p53 family members cooperate in cell cycle regulation 
and apoptosis. In MCF7 cells, p73 and p63, but not p53, are 
modulated during the cell cycle with a peak in S phase, and 
their silencing suppresses proliferation [Lefkimmiatis, K et al. 
2009]. In cycling cells, p73 and p63 are bound to the p53-
responsive elements (REs) in the regulatory regions of cell 
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cycle progression genes. However, when the cells are arrested 
in G0-G1, p73 detaches from the REs and is replaced by p53, 
which functions as transcriptional repressor. When the cells 
move into S-phase, p73 is recruited again and p53 is displaced 
or is weakly bound to the REs. Thus, elevated concentrations of 
p73 and p63, as it is found in many cancers, could cause the 
aberrant activation of cell growth progression genes and 
therefore contribute to cancer initiation or progression.  
(5) The interaction among the p53 family members is also critical 
for the control of p73-dependent cisplatin sensitivity. In triple-
negative primary breast cancers, that commonly exhibit 
mutational inactivation of p53, ΔNp63 and TAp73 isoforms are 
co-expressed. This subset of breast cancer exhibited cisplatin 
sensitivity that was dependent on TAp73 [Leong, C.O et al. 
2007]. The ΔNp63α isoform promoted survival of breast cancer 
cells by binding TAp73, thereby inhibiting its pro-apoptotic 
activity. In response to treatment with cisplatin, but not other 
chemotherapeutic agents, TAp73 underwent c-Abl-dependent 
phosphorylation, which promoted dissociation of the 
ΔNp63α/TAp73 protein complex followed by TAp73-dependent 
transcription of Bcl-2 family members and apoptosis. Breast 
tumors with the above described intact pathway would be 
predicted to be platinum sensitive and have high levels of 
ΔNp63 to repress TAp73 activity. [Silver, D.P. et al. 2010] 
Similarly, in HNSCC patients, high levels of ΔNp63 are 
associated with a good response to platinum-based 
chemotherapy [39]. In HNSCC cells, ΔNp63 inhibits the activity 
of TAp73 and suppresses TAp73-dependent apoptosis [Rocco, 
J.W et al. 2006]. TAp73 is necessary for apoptosis following 
knockdown of ΔNp63, and siRNA-mediated inhibition of TAp73 
expression reduces HNSCC cellular sensitivity to cisplatin. 
Moreover, as shown by immunoprecipitation, ΔNp63 also forms 
a complex with TAp73 in HNSCC, therefore it is possible that a 
mechanism as that described in triple-negative breast cancer 
also takes place in HNSCC. These results should also be 
considered in relation to the effects of ΔNp63 in promoting cell 
survival, which behaves as a paradox to the cisplatin sensitivity 
of p63-expressing tumors. Indeed, in HNSCC, siRNA-mediated 
reduction in the endogenous p63 levels results in more tumor 
cells being killed by radiation and cisplatin, demonstrating a 
pro-survival role for p63 [Thurfjell, N et al. 2005]. These 
combined data indicate that the cooperative or antagonistic 
interactions between p53-family members are important for the 
regulation of the cell cycle and apoptosis, and thus also for 
tumor development. Moreover, there is substantial evidence 
that ΔNp63 expression is a predictor of chemosensitivity to 
cisplatin. 
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Ultimately, a tumor suppressor is a gene that is frequently lost 
or inactivated in human cancers. Based on this definition, 
however, drawing analogies between p63 and p53 is like ―fitting 
a square peg into a round hole‖. With regards to classical 
features of a tumor suppressor, p63 contrasts markedly with 
p53: it is rarely mutated in human cancers [Moll UM, Slade N 
2004]. Indeed, the majority of tumors maintain p63 expression, 
and in many cases the p63 locus is amplified or p63 appears to 
be overexpressed, consistent with p63 performing a pro-
proliferative or oncogenic role.  
A genome-wide microarray screen of non-small cell lung cancer 
revealed that the 3q26–29 locus encompassing p63 is 
frequently amplified in squamous cell carcinomas of the lung, 
suggesting that overexpression of p63 facilitates tumorigenesis 
[Tonon G et al. 2005]. A study of  wide number of esophageal 
tumor samples demonstrates that there was no correlation 
between p63 expression and p53 mutational status, thus 
suggesting that upregulation of p63 in squamous cell 
carcinomas is independent of p53. [Cui R, et al. 2005]. 
However, metastatic tumor types have been reported to lose 
p63 expression, thereby suggesting that loss of p63 might 
induce tumor metastases [Urist MJ et al. 2002, Koga F et al. 
2003]. Whether more malignant tumors with undetectable p63 
expression arose from progenitor cells that were expressing 
p63 or whether epithelial–mesenchymal transition, that 
frequently accompany tumor progression, occurs in p63 null 
tumors awaits further investigation.  
 
1.1.7 p63 in cell adhesion, migration, and 
metastasis  
 
An increasing number of data indicate that p63 is involved in 
cell migration and adhesion and thus also in processes 
connected with metastasis and wound healing. In HNSCC, p63 
was shown to regulate the expression of adhesion-related 
genes and contribute to cell invasion and migration [Gu, X.L et 
al. 2008]. In squamous cell carcinoma disruption of p63 was 
found to trigger the expression of genes associated with a 
higher potential to metastasize and invade [Barbieri, C.E et al. 
2006]. Additionally, in vitro cell migration assays showed that 
loss of p63 leads to increased cell migration of squamous 
carcinoma cells[Barbieri, C.E et al. 2006]. 
In a recent manuscript, Adorno et al. (2009) described that in 
cells expressing mutant p53, p63 acts as an antagonist of 
TGFβ-mediated tumor invasiveness and metastasis. 
Specifically, p63 transcriptional activity was found to be 
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inactivated by a mutant p53-Smad complex  induced by TGFβ. 
[Adorno, M et al. 2009]. 
Similarly, knockdown of p63 expression caused down-
regulation of cell adhesion associated genes, cell detachment 
and anoikis in mammary epithelial cells and keratinocytes 
[Carroll, D.K et al. 2009]. Most recently, Su et al. showed that 
TAp63 suppresses metastasis by regulating the microRNA 
processing complex [Su, X et al. 2010]. These findings 
uncovered a new role of p63 as a negative regulator of 
metastasis. Bamberger et al. suggested the role of p63 
isoforms in the healing of skin wounds, which is achieved by 
extensive migration and hyperproliferation of keratinocytes 
[Bamberger, C et al. 2005]. ΔNp63 variants were found at high 
levels in basal and suprabasal keratinocytes of the 
hyperproliferative wound epithelium, TAp63 variants were also 
expressed in wound keratinocytes. Thurfjell et al. compared the 
p63 status in normal oral wounds and in HNSCC, two situations 
that represent self-limiting and non-self-limiting 
processes[Thurfjell, N et al. 2006]. They found that both 
processes require upregulation of TA and ΔNp63. However, in 
wounds, there was a down-regulation in TAp63 mRNA levels 
but not in protein expression, indicating a post translational 
mechanism of TAp63 stabilization. In conclusion, a finely tuned 
balance between of p63 isoform transcription and protein 
stabilization appears to be required in order to drive normal 
epithelial proliferation and differentiation.  
 
 
1.2 YB-1: a newly identified p63 partner  
 
Unequivocal establishment of the biological role of p63 is 
complicated by the fact that this protein exists in multiple 
isoforms with sometimes seemingly contradictory activities.  
Furthermore, the activity of each specific isoform can be deeply 
modified or modulated through the dynamic interaction with 
particular molecular partners. In the laboratory where I carried 
out the work for my PhD thesis, a total of 50 potential Np63 
interacting proteins were isolated by a functional proteomic 
approach [Amoresano et al., 2010]. Several RNA/DNA binding 
proteins were identified including the YB-1 oncoprotein. The 
finding that ΔNp63 is engaged in complexes with YB-1 laid the 
premises for my work aimed to understand the functional role of 
their association in the control of cell proliferation and 
trasformation.  
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1.2.1 YB-1 STRUCTURAL ORGANIZATION  
 
Mammalian Y Box Binding protein 1 (YB-1) is a 36 kDa protein 
showing abnormal electrophoretic mobility with an apparent 
molecular weight of 50-kDa. The protein is enriched in Arg, Pro, 
Gly, and Gln and exhibits a pI of about 9.5. Three structural 
domains can be distinguished in YB-1 (Fig. 2): a small N-
terminal domain rich in Ala and Pro (A/P domain), a central 
cold-shock domain (CSD), and a C-terminal domain (C domain) 
with alternating clusters of positively and negatively charged 
amino acid residues (four clusters of each sign) [Matsumoto K., 
Wolffe A.P. 1998; Sommerville J. 1999]. The CSD is a highly 
evolutionarily conserved domain.  
In bacteria, proteins consisting of the CSD domain alone are 
known as the major cold-shock proteins: synthesis of some of 
these proteins is activated at low temperature and facilitates 
adaptation of bacteria to cold conditions [Graumann P.L., 
Marahiel M.A. 1998]. Bacterial major cold-shock proteins and 
the CSD of YB-1 have the same β-barrel spatial structure 
[Schindelin H  et al. 1993; Kloks C.P et al. 2002]. The spatial 
structures of the N and C domains of YB-1 are still unknown. 
However, it is generally believed that the C domain assumes 
various conformations depending on its interaction partner 
[Manival X. Et al. 2001; Ivanyi-Nagy R et al. 2005]. Like the 
bacterial main cold-shock proteins, eukaryotic CSD harbors 
conserved motifs RNP1 and RNP2 and interacts both with DNA 
and with RNA [Kohno K et al. 2003; Sommerville J. 1999; 
Graumann P.L., Marahiel M.A. 1998]. The C domain has a 
nonspecific affinity for RNA and DNA and, presumably, utilizes 
its positively charged clusters to interact with negatively 
charged phosphate groups of nucleic acids. Isolated YB-1 
forms large homo-multimeric complexes, with a molecular 
weight reaching 800 kDa and a sedimentation coefficient 
reaching 20S [Evdokimova V.M et al. 1995, Gaudreault I et al. 
2004]. In electron and atomic force microscopy on a substrate, 
such multimers are seen as rounded uniform structures of 30–
40 nm in diameter and 8–10 nm in height [Murray M.T et al. 
2004]. The protein is multimerized probably as a result of 
interactions between differently charged C domain clusters. The 
interaction of YB-1 with other proteins can involve each of the 
three domains alone or their combinations [Kohno K et al. 2003, 
Sorokin A.V et al. 2005].  
YB-1 belongs to a large family of proteins possessing CSD. The 
embryonic proteins accumulate to a high percentage in 
gametes and play a role in packaging and masking mRNA in 
the cytoplasm [Matsumoto K., Wolffe A.P. 1998; Sommerville J. 
1999]. Compared with YB-1 these proteins have not only CSD 
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with a fully identical amino acid sequence, but also a similarly 
organized C domain. 
For instance, Xenopus embryonic protein FRGY2 is similar to 
somatic protein FRGY1 in having the same number of positive 
and negative amino acid clusters in the C domain [Murray M.T 
et al. 1992; Wolffe A.P.et al. 1992]. The embryonic and somatic 
proteins are near identical in pI and the amino acid composition. 
At the same time, beyond CSD the amino acid sequence 
identity of the two proteins is below 30%. FRGY2 is 
dephosphorylated upon fertilization of Xenopus eggs, which, 
possibly, decreases its affinity for RNA and provides a 
mechanism of mRNA demasking [Sommerville J. 1990; 
Sommerville J., Ladomery M. 1996]. Embryonic FRGY2 is 
replaced by somatic FRGY1 during further embryo 
development; the replacement is completed by the end of 
gastrulation [Wolffe A.P et al. 1992, Tafuri S.R., Wolffe A.P. 
1990].  
In Xenopus oocytes the YB-1 protein exists in two isoforms, 
known as p54 and p56 [Murray M.T., Schiller D.L., Franke 
W.W. 1992]. Chironomus also has two isoforms, Ct-p40/p50, 
that differ only in the C-terminal amino acid sequence and, 
presumably, are encoded by two mRNAs produced from one 
primary transcript via alternative splicing [Soop T et al. 2003]. 
Both Ct-p40 and p50 were found in the larval salivary glands, 
while only one isoform, Ct-p40, occurs in cultured embryonic 
cells. Other proteins related to YB-1 have greater structural 
differences and in some cases similarity is restricted to the 
presence of CSD [Matsumoto K., Wolffe A.P. 1998, 
Sommerville J. 1999]. 
 
1.2.2 YB-1 IS A MULTIFUNCTIONAL DNA/RNA-
BINDING PROTEIN 
 
Mammalian YB-1 regulates various activities of cells and the 
whole organism, including cell growth, differentiation, stress 
response, and programmed cell death (apoptosis) [Skabkin M.A 
et al. 2004]. YB-1 is necessary for cell adaptation to growth at 
suboptimal temperatures [Matsumoto K. et al. 2005]. YB-1 
increases cell resistance to ionizing radiation and xenobiotics, 
and its transfer into the cell nucleus is regarded as the earliest 
marker of multiple drug resistance in cancer cells [Kohno K et 
al. 2003, Kuwano M et al. 2004]. The YB-1 content in some 
tumors (breast cancer, lung cancer, carcinoma of the prostate, 
osteosarcoma, etc.) is higher than in normal cells of the same 
tissue. Moreover, the YB-1 concentration in non-small-cell lung 
cancer is so high that YB-1 has been included in the list of the 
12 proteins whose amounts changed most significantly upon 
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cell malignant transformation. Enforced expression of YB-1, 
causes centrosome amplification and leads to numerical 
chromosome instability and oncogenic transformation of cells 
[Bergmann S et al. 2005]. In other words, YB-1 can be regarded 
as a tumor marker. 
 
Figura 2 The Structure and Functions of YB-1. YB-1 is made up of the N-terminal, cold shock (CSD) and C-terminal domains 
(CTD). These domains have unique functions. The N-terminal is necessary for transactivation whereas the CSD is important for 
RNA/DNA binding. Most of the characterized protein-protein interactions occur on the CTD. The CSD and CTD also work 
together to facilitate nuclear trafficking. Cellular trafficking is furthermore regulated by the nuclear localization signal in the C-
terminal domain as well as the cytoplasmic retention signal also located in this region of the protein 
Although acting as an oncoprotein in many cases, YB-1 can 
also prevent oncogenic transformation of cells via the inositol 3-
phosphate/ Akt-kinase signaling pathway [Bader A.G et al. 
2003]. Suppression of YB-1 synthesis in knock-out mice caused 
postnatal death, and exhibit exencephaly associated with 
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defective  neural tube closure and abnormal patterns of cell 
proliferation within the neuroepithelium. [Lu Z.H. et al. 2005]. 
One of the key function of YB-1 consists in the relatively unique 
ability of this protein to interact with both DNA and RNA [Kohno 
K et al. 2003, Matsumoto K., Wolffe A.P. 1998]. YB-1 has a 
general high affinity for any nucleotide sequence in DNA or 
RNA, although, in some conditions, particular sequences are 
bound preferentially [Minich W.B et al. 1993– Coles L.S et al. 
2004]. YB-1 specifically binds to certain regulatory DNA 
sequences, in particular, promoter and enhancer regions 
containing Y boxes (inverted CCAAT motifs in a special 
surrounding).  
YB-1 regulates, positively or negatively, transcription of genes 
involved in relevant cellular pathways [Kohno K.,et al. 2003 
Swamynathan S.K et al. 1998. These include growth factor 
genes, division genes , apoptosis, in the immune response, 
multiple drug resistance, stress responses and some viral 
genes. 
YB-1 displays a higher affinity for single stranded regions of 
DNA and RNA, and substantially decreases the melting 
temperature of double helices [Zasedateleva O.A et al. 2002, 
Evdokimova V.M et al. 1995– Izumi H. Et al. 2001]. In fact, in 
vitro experiments have shown that YB-1 is able to accelerate 
the annealing of complementary strands of nucleic acids, by 
three orders of magnitude. Under physiological conditions, it 
favours the formation of the longest and most perfect duplexes 
[Skabkin M.A et al. 2001].  
The only exception is DNA double helices with poly(G) blocks, 
whose melting temperature is significantly increased by YB-1 
[Zasedateleva O.A et al. 2001].  
YB-1 has a higher affinity for DNA regions with a damaged 
secondary structure and promotes DNA repair. Accelerating the 
exchange of complementary nucleotide strands in double 
helices, YB-1 presumably contributes to DNA recombination 
[Skabkin M.A et al. 2001, Ise T et al. 1999]. There is evidence 
that YB-1 plays a role in DNA replication [Levenson V.V et al. 
2000, En-Nia A et al. 2005]. Thus, YB-1 is probably involved in 
all DNA-dependent processes. During transcription YB-1 binds 
to pre-mRNA on chromosomes and accompanies mRNA 
molecules throughout their life [Kohno K et al. 2003, Soop T et 
al. 2003].  
In the cell nucleus, YB-1 plays a role in alternative splicing of 
pre-mRNA [Stickeler E. Et al. 2001, Chansky H.A. et al. 2001]. 
In the cytoplasm of mammalian cells, almost all YB-1 molecules 
are associated with translated or non translated mRNAs, 
determining their functional activity [Davydova E.K. et al. 1997, 
Evdokimova V.M., Ovchinnikov L.P. 1999], stability 
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[Evdokimova V et al. 2001], and the localization of 
translationally active mRNAs on the actin skeleton [Ruzanov 
P.V et al. 1999]. It is clear that YB-1 is involved not only in DNA 
dependent processes, but in all steps of mRNA biogenesis and 
functioning as well. The various effects of YB-1 on mRNA-
dependent processes, including global regulation of protein 
synthesis, are due to its relatively non specific interactions with 
mRNA [Ovchinnikov L.P. et al. 2001]. At the same time, the 
specific affinity of YB-1 can serve to selectively regulate 
synthesis of certain proteins, including YB-1 itself [Coles L.S. et 
al. 2004, Giorgini F et al. 2001, Skabkina O.V. et al. 2005]. 
The involvement of YB-1 in particular cell processes depends 
on its distribution between the nucleus and the cytoplasm. YB-1 
is mostly located in the cytoplasm [Jurchott K. et al. 2003, 
Sorokin A.V. et al. 2005]. However, YB-1 is transferred into the 
cell nucleus for a relatively short period at the G1/S transition 
during the cell cycle [Jurchott K. et al. 2003], activating 
transcription of the cyclin A and B1 genes. The transfer of YB-1 
into the nucleus has been observed in response to UV light and 
DNA-damaging chemicals [Koike K et al. 1997, Gaudreault I et 
al. 2004]. In addition, YB-1 is transferred into the nuclei of 
cultured vascular endothelial cells in response to thrombin and, 
acting as a transcription factor, activates the expression of 
genes involved in endothelial cell differentiation [Stenina O.I et 
al. 2001]. 
YB-1 contains the nuclear localization and cytoplasmic retention 
signals (Fig. 2) [Jurchott K et al. 2001, Stenina O.I et al. 2001, 
Bader A.G., Vogt P.K. 2005]. The cytoplasmic retention signal 
is in the C-terminal portion of the molecule. Both full-length YB-
1 and its form truncated at the C end have been found in the 
cell nucleus [Sorokin A.V et al. 2005]. The mechanism of 
transferring full length YB-1 into the nucleus is as of yet unclear. 
In endothelial cells treated with thrombin and in NIH3T3 cells 
exposed to genotoxic stress upon treatment with doxorubicin 
YB-1 is transferred into the nucleus owing to the cleavage of its 
C-terminal region containing the cytoplasmic retention signal 
[Sorokin A.V et al. 2005, Stenina O.I et al. 2001]. The cleavage 
is catalyzed by the proteasome, because the proteasome 
inhibitor MG132 prevents both the C cleavage of YB-1 and its 
transfer into the nucleus [Sorokin A.V et al. 2005]. The selective 
proteasomal C-cleavage of YB-1 has been reproduced in vitro 
with the 20S core proteasome and has been shown to involve 
neither ATP nor ubiquitination of YB-1. The protein is cleaved 
only when non bound to RNA. It is thought that YB-1 can enter 
the 20S proteasome channel with catalytical activities because 
its C-terminal region is unstructured [Sorokin A.V et al. 2005]. 
[Digitare il testo] 
 
39  
 
C-truncated YB-1 retains the capability of activating 
transcription of certain genes [Stenina O.I et al. 2001]. 
 
 
1.2.3 NONSPECIFIC INTERACTION OF YB-1 WITH 
mRNA 
 
YB-1 was identified, more than 30 years ago, as a universal 
major protein of cytoplasmic mRNPs [Morel C. et al. 1971; 
Blobel G. 1972]. The protein, known as p50 at that time, was 
detected in mRNP preparations from various cells and 
organisms [Preobrazhensky A.A., Spirin A.S. 1978; Dreyfuss G. 
1986]. YB-1 displays an extremely high affinity for mRNP ( Kd ~ 
4 nM for the globin mRNA) and approximately the same affinity 
for the bacterial 16S rRNA in vitro [Minich W.B et al. 1993], 
suggesting a high affinity for a great diversity of nucleotide 
sequences. There is evidence that the efficiency of binding with 
YB-1 sharply drops when the size of RNA is below a certain 
threshold (about 50 nucleotides) [Bouvet P et al. 1995, Jiang W. 
et al.1997].  
YB-1 protects RNA from chemical agents. The aspecific binding 
of YB1 to mRNA occurs with the nucleic-acid sugar-phosphate 
backbone [Pisarev A.V. et al. 2002]. YB-1 utilizes both the CSD 
and the C-terminal domain to interact with RNA [Izumi H. et al. 
2001, Pisarev A.V. et al. 2002]. The binding of CSD to RNA 
probably involves positively charged and aromatic residues of 
RNP1 and RNP2, while the C-terminal domain seems to bind 
with clusters of positively charged residues [Blobel G. 1973]. 
However, covalent cross-linking experiments, performed to 
study the interaction of YB-1 with the mRNA 5’cap, revealed 
that the CSD but not the C domain, of YB-1 displaces the eIF4E 
initiation factor from its complex with the 5’cap of mRNA and 
that mutations affecting the aromatic residues of RNP1 
completely abrogated its interaction with the cap [Pisarev A.V. 
et al. 2002]. 
The free non translated mRNPs contains only YB-1 as the 
major core protein.  In translated polysomal mRNPs, instead, 
YB-1 is present with the poly(A)-binding protein (PABP) [Blobel 
G. 1973; Minich W.B., Ovchinnikov L.P. 1992]. The YB-1 
content in polysomal mRNP is half as high as in free mRNP 
[Minich W.B et al. 1993]. This indicates that, when mRNA 
changes from the non-translated to the translated state, a large 
amount of YB-1 dissociates from it and PABP binds to the 
poly(A) tail. YB-1 binds different homopolyribonucleotides with 
different affinities [Minich W.B et al. 1993]. The affinity 
decreases in the following order: poly(G) > poly(U) > poly(A) > 
poly(C). The affinity of YB-1 for poly(A) is comparable with the 
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affinity of PABP for the same sequence. Thus, the two major 
proteins of mRNP can compete with each other for binding to 
the poly(A) tail of mRNA.  
YB-1 exerts a dual effect on translation, stimulating it at a low 
YB-1/mRNA ratio, while completely suppressing it at a higher 
YB-1/mRNA ratio [Minich W.B., Ovchinnikov L.P. 1992]. 
Maximal stimulation of protein synthesis was observed at the 
YB-1/mRNA ratio characteristic of polysomal mRNP. 
Translation is completely suppressed when the YB-1/mRNA 
ratio is close to that in free non-translated mRNP. Stimulation 
and suppression of translation by YB-1 occur only at initiation 
[Evdokimova V.M et al. 1998; Nekrasov M.P et al. 2003]. To 
stimulate initiation YB-1 most likely promotes the scanning of 
the 5'-untranslated region (5'-UTR) by the 43S preinitiation 
complex searching for the initiation triplet. YB-1 suppression of 
translational start leads to the accumulation of mRNA in the 
form of free mRNP.  
This mechanism of suppression is only partly explained by 
PABP displacement from its mRNA complex, as YB-1 inhibits 
not only translation of poly(A)+/mRNAs, but also that of poly(A)-
/mRNAs.  
YB-1 blocks the interaction of mRNA with initiation factors of 
translation, primarily eIF4G [Nekrasov M.P et al. 2003]. In 
addition YB-1 stabilizes mRNA both in vitro and in vivo by a 
mechanism requiring the 5'-terminal cap [Evdokimova V. Et al. 
2001, Chen C.Y. et al. 2000]. It is of interest that different 
domains of YB-1 are responsible for inhibition of translation and 
mRNA stabilization [Evdokimova V. Et al. 2001; Nekrasov M.P 
et al. 2003]. Stabilization of mRNA is due to the YB-1 fragment 
containing CSD and the A/P domain while the translation 
inhibitory activity belongs mostly to the C domain. These two 
fragments displace different subunits of eIF4F from its complex 
with mRNA: AP-CSD displaces the cap-binding subunit eIF4E, 
while the C domain displaces the eIF4G subunit. 
 
 
1.2.4 SPECIFIC INTERACTION OF YB-1 WITH 
mRNA 
 
The regulation of protein synthesis is driven by particular 
proteins or RNAs that interact with 3'- or 5'-UTR mRNA 
sequences [Wilkie G.S. et al. 2003]. Recently, a regulatory 3'-
UTR sequence was found in YB-1 mRNA [Skabkina O.V. et al. 
2003]. A short RNA fragment containing this sequence strongly 
suppressed YB-1 synthesis when added to a cell-free 
translation system. Further studies demonstrated that the 
fragment inhibited translation of YB-1 mRNA as well as that 
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other transcripts. UV-inducible crosslinking experiments 
revealed that YB-1 and PABP proteins specifically bind to this 
fragment [Skabkina O.V. et al. 2003]. The specific binding of 
PABP to exogenous poly(A) inhibited translation of YB-1 mRNA 
and was accompanied by the accumulation of mRNA in the 
form of free mRNP [Skabkina O.V. et al. 2003]. Inhibition was 
observed even when the YB-1 mRNA was devoid of the poly(A) 
tail. [Skabkina O.V. et al. 2005].  
As in the case of depletion of PABP, free mRNP accumulated 
as a result of such a suppression. Thus, initiation was 
suppressed at the step of mRNA binding to the 43S preinitiation 
complex, or at an earlier step of mRNA interaction with the 
translation initiation factors in both cases.  
The specific binding of YB-1 to certain mRNAs affects both 
nuclear and cytoplasmic processes. Several examples are 
known for the role of Y-box binding proteins in selective mRNA 
stabilization. For instance, (1) YB-1 binds to an A/C-rich region 
of exon 4 of the CD44 pre-mRNA thereby increasing the rate of 
exon incorporation into the mature mRNA [Chansky H.A. et al. 
2001], (2) The specific binding of Chk-YB-1 to the Rous 
sarcoma virus RNA suppressed synthesis of viral p19Gag, 
presumably, at the translational level [Swamynathan S.K. et al. 
2000]. (3) YB-1 is contained in a multiprotein complex 
preventing degradation of the renin mRNA [Skalweit A et al. 
2003]. (4) YB-1 selectively binds to the sequence AACCUCUU 
in the 5'-UTR of the vascular endothelial growth factor mRNA 
and, along with PTB, another RNA-binding protein, stabilizes 
this mRNA [Coles L.S et al. 2004]. A similar sequence was 
found in the 5'-UTR of the interleukin 2 mRNA. Its interactions 
with YB-1 and nucleolin are necessary for the stabilization of 
the interleukin 2 mRNA when T cells are activated by JNK 
[Chen C.Y et al. 2000]. Thus, specific interactions of Y-box-
binding proteins with certain mRNA sequences play an 
important role in the selective regulation of mRNA translation 
and stability. 
 
1.2.5 PI3K/Akt and YB-1 
 
Several components of the PI3K/Akt signaling pathway are 
known to be responsible for YB-1 phosphorylation. This 
pathway is activated by several different mechanisms in 
cancers, including somatic mutations and amplification of genes 
encoding key components (Reference).  
Akt is often activated in breast cancer but not in normal breast 
epithelial cells (Kucab et al. 2004) and is able to transform 
breast epithelial cells into malignant phenotypes (Zhao et al. 
2003; Zhang et al. 2003).  
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Moreover, co-expression of constitutively active Akt1 (CA-Akt1) 
and mutant polyomavirus T antigen was found to be 
responsible for mammary tumor formation in nude mice 
(Hutchinson et al. 2001). Finally, clinical studies have 
demonstrated a relationship between Akt and tumor relapse 
and poor prognosis (Bellacosa et al. 1995).  
By screening primary tumor tissue microarrays,  was found that 
phosphorylated Akt (pAkt) was associated with YB-1 in breast 
cancer (Sutherland et al. 2005). Akt1 targets Serine 102 of YB-
1, which is located in the CSD (Sutherland et al. 2005). Later 
on, it was shown that this occur upon IGF-1 stimulation and 
treatment with Wortmannin, a PI3K inhibitor, fully blocked S102 
phosphorylation of YB-1 (Evdokimova et al. 2006). 
Phosphorylation of YB-1 by Akt was shown to affect YB-1 
nuclear trafficking, DNA binding and/or YB-1 mRNA translation. 
Inhibition of YB-1(S102) phosphorylation, by site directed 
mutagenesis, impairs YB-1 nuclear translocation (Sutherland et 
al. 2005).  
Studies from Bader and co-workers, in chicken embryo 
fibroblasts, claim that YB-1 suppresses Akt-mediated oncogenic 
transformation by inhibiting protein synthesis (Bader et al. 2003; 
Bader et al. 2005). In striking contrast with the majority of 
studies on AKT, these authors indicate a role for YB-1 as a 
tumor suppressor rather than an oncogene.  
As previously mentioned, YB-1 nuclear translocation is believed 
to be regulated by the PI3K/Akt pathway, through S102 
phosphorylation. YB-1 was shown to have a non canonical NLS 
as well as a cytoplasmic retention site (CRS) in the C-terminal 
domain (Bader et al. 2005). Jürchott and co-workers suggested 
that both the carboxy-terminal  region and the CSD are involved 
in YB-1 nuclear shuttling (Jürchott et al. 2003). It seems 
reasonable to postulate that S102 phosphorylation activates the 
NLS and/or inhibits the CRS function. For instance, 
phosphorylation of S102 may induce YB-1 conformational 
change, which masks the CRS and/or reveals the NLS; 
alternatively, it might control the DNA binding activity of YB-1. 
Remarkably, wild type YB-1 binds to the 2 kb fragment of the 
EGFR promoter while the YB-1(A102) mutant was unable to do 
it (Wu et al. 2006). One may argue that disruption of S102 
blocked nuclear translocation of YB-1 thus prevented the 
binding of YB-1 to the EGFR promoter. However upon careful 
inspection, mutation of S102 to alanine did not completely block 
nuclear shuttling of YB-1. In fact, there was still approximately 
50% of YB-1(A102) still present in the nuclear compartment 
(Sutherland et al. 2005).  
Finally, it was recently demonstrated that Akt-mediated 
phosphorylation of YB1-S102 prevented YB-1 from binding to 
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the capped 5’ terminus of mRNA thereby promoting the 
translation of oncogenes such as IGF-1, VEGF and FOS 
(Evdokimova et al. 2006). The release of YB-1 from cytoplasmic 
mRNAs can result in YB1 nuclear translocation (Stenina et al. 
2001). The proposed model is that YB-1 phosphorylation by Akt 
allows latent pro-proliferative gene transcripts to enter into the 
translational machinery thus supporting the idea that YB-1 is 
actually working as an oncoprotein (Bader et al. 2003; 
Evdokimova et al. 2006).  
Akt is the first kinase to be shown to regulate YB-1. However, 
Phospho-motif scanner softwares also predicted that the PI3K 
p85 subunit may be able to phosphorylate Tyr197 in the C-
terminal domain of YB-1.  
Interestingly, Tyr197 is located within the NLS of YB-1 (residue 
183–202), which raises the question of whether or not YB-1 
subcellular localization is regulated by phosphorylation of this 
residue by PI3K (Bader et al. 2005). This could explain why the 
PI3K inhibitor wortmannin, by blocking both PI3K and Akt, 
completely abolished YB-1 phosphorylation induced by IGF-1 
stimulation, whereas mutation of S102 to alanine was not able 
to fully prevent YB-1 phosphorylation (Evdokimova et al. 2006). 
On the other hand, the glycogen synthase kinase 3 (GSK3), 
which is negatively regulated by Akt (Diehl et al. 1998), can 
potentially phosphorylate Ser21 located in the N-terminal 
domain of YB-1 and affect its transcriptional activity. Coles et al. 
reported that GSK3β phosphorylated the N-terminus of YB-1, 
enhancing the ability of YB-1 to repress the vascular endothelial 
growth factor (VEGF) promoter (Coles et al. 2005). This study 
also implies the involvement of Akt/GSK3β/YB-1 in tumor 
angiogenesis. In conclusion, YB-1 phosphorylation via PI3K/Akt 
signaling is expected to exert a profound effect on tumor 
pathogenesis and/or progression. 
 
1.2.6 How does YB-1 play a role in cancer? 
 
YB-1 has been shown to be associated with many malignancies 
including colorectal carcinomas (Shibao et al. 1999), prostate 
cancer (Gimenez- Bonafe et al. 2004), osteosarcoma (Oda et 
al. 1998), ovarian serous adenocarcinoma (Kamura et al. 1999; 
Yahata et al. 2002), lung cancer (Shibahara et al. 2001; Gu et 
al. 2001), synovial sarcoma (Oda et al. 2003) and breast cancer 
(Bargou et al. 1997; Janz et al. 2002; Rubinstein et al. 2002; 
Huang et al. 2005; Wu et al. 2006). Much less is known about 
the role of YB-1 in childhood cancers. The first study of its kind 
was published in 2007; the authors showed that YB-1 is a 
feature of pediatric glioblastoma multiforme (GBM) (Faury et al. 
2007). This was discovered initially by comparing pediatric and 
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adult GBM gene expression profiles. In this study, it was 
determined that YB-1 is more frequently over-expressed in 
pediatric GBM compared to adult GBM.   
Given that expression of YB-1 is deregulated in so many tumor 
types, it seemed obvious to think that it plays an important role 
in cancer development.  
YB1 transgenic mice develop mammary tumors and their tumor 
cells exhibit chromosomal instability and a high content of 
binucleate cells, most of which were tetraploid.  
It was speculated that YB-1 promotes breast tumor formation 
and/or growth by accelerating cell cycle progression and 
escaping DNA damage check points (Bergmann et al. 2005). 
Whether or not YB-1 plays a similar causative role in the 
development of other types of cancer is unknown at this time. 
Independently of whether YB-1 is instrumental in the 
development of cancer or not, it is believed to play an important 
role in mediating the growth of malignant cells.  
The growth and survival of several cancer cells are dependent 
upon YB-1. For example, melanoma, adenocarcinoma, 
hepatoma, fibrosarcoma and colon cancer cells die when YB-1 
is knocked out with antisense RNA (Swamynathan et al. 2002).  
It was also revealed an association between YB-1 and 
expression of two epidermal growth factor receptors, EGFR and 
Her-2. Wild type YB-1, but not YB-1A102, upregulates the 
expression of these receptors. Since EGFR and Her-2 are two 
critical breast carcinoma markers, YB-1 can potentially promote 
breast cancer growth by stimulating the expression of both 
receptors (Wu et al. 2006). Accordingly, enforced expression of 
YB-1 in immortalized breast epithelial cells causes enhanced 
cell growth associated to the induction of EGFR (Berquin et al. 
2005). It can therefore be generally stated that YB-1 is essential 
for the growth of breast cancer cells. (Bargou et al. 1997; 
Rubinstein et al. 2002; Janz et al. 2002, Wu et al. 2006). 
Much of the work on YB-1 in cancer is centered around its role 
as a transcription factor while less is known about how this 
factor affects translation. 
As a transcription factor, YB-1 binds to the inverted CCAAT 
element in the Y-box (Didier et al. 1988; Goldsmith et al. 1993; 
Norman et al. 2001; Jürchott et al. 2003). YB-1 is also able to 
recognize Y-boxes without the canonical consensus site 
(Mertens et al. 1997; Higashi et al. 2003; Lasham et al. 2003), 
and sequences flanking the Y-box have been suggested to 
contribute to YB-1:DNA interaction (Didier et al. 1988; Norman 
et al. 2001). YB-1 up-regulates the transcription of CYCLIN A 
(Jürchott et al. 2003), CYCLIN B1 (Jürchott et al. 2003), 
TOPOISOMERASE II α (Shibao et al. 1999), and DNA 
POLYMERASE α (En-Nia et al. 2005), implying that YB-1 
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enhances cell growth possibly promoting transcription of both 
cell cycle progression and DNA replication associated genes. 
Swamynathan et al. show that cells with targeted disruption of 
one allele of YB-1 displayed defects in the cell cycle 
progression and reduction of cell growth (Swamynathan et al. 
2002). Although it has been suggested that YB-1 interacts with 
the proliferating cell nuclear antigen (PCNA; Ise et al. 1999) and 
DNA polymerase δ (Gaudreault et al. 2004), it is unknown 
whether or not YB-1 is part of the DNA replication holoenzyme. 
Due to its role in cell growth, YB-1 is implicated in cancer 
pathogenesis.  
YB-1 was also shown to control the expression of phosphatase 
PTP1B (Fukada et al. 2003), matrix metalloproteinase- 2 (MMP-
2) (Mertens et al. 1997; Mertens et al. 2002), matrix 
metalloproteinase-12 (MMP-12) (Samuel et al. 2005), collagen 
α 1(I) (Norman et al. 2001), and collagen α 2(I) (Higashi et al. 
2003; Dooley et al. 2006), implying its involvement in 
mechanism controlling cell adhesion, motility and invasion. The 
transcriptional activity of YB-1 on MMP-2 was demonstrated to 
be dependent on the interaction with two other transcription 
factors, namely the activating protein-2 (AP-2) and p53 
(Mertens et al. 2002). Furthermore, YB-1 promotes the 
expression of several drug resistance genes, including the p-
glycoprotein encoded by the multi-drug resistance gene 
(MDR1) (Goldsmith et al. 1993; Stein et al. 2001), multi-drug 
resistance related protein-1 (MRP 1) (Stein et al. 2001), as well 
as the major vault protein (MVP) (Stein et al. 2005).  
The ability to regulate genes related to metastasis and drug 
resistance suggests that YB-1 may be a marker for tumor 
aggressiveness and may predict the response to 
chemotherapies. 
 
1.2.7 Why is YB-1 over-expressed in cancer 
 
YB-1 maps on chromosome 1p34.1, and genetic alterations 
encompassing this region were frequently found in lung, colon 
and breast cancer (Henderson et al. 2005). Upon closer 
inspection and fine mapping of 1p34 in lung cancer cell lines, it 
became clear that the most commonly amplified region was at 
1p34.2, which includes the myc loci (Kim et al. 2006). 
Similarly, gene amplifications were reported in lung cancer at 
1p34.3 to 1p34.4 (Henderson et al. 2005) but again this region 
does not include the YB-1 gene. Furthermore, there was no 
evidence for gene amplification at 1p34 in breast cancer cell 
lines known to over-express YB-1 (Shadeo et al. 2005).  
Thus, YB-1 overexpression, in breast and other epithelial 
cancers, does not appear to be due to a gain in copy number. 
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Alternatively, YB-1 dysregulation could be due to transcriptional 
activation. To date, very few studies have addressed the 
transcriptional regulation of the YB-1 promoter. In one report, 
multiple E-boxes and GF-boxes on the YB-1 gene promoter 
were bound by c-Myc, which interacts with p73 to regulate YB-1 
expression (Uramoto et al. 2002).   
Comparison between YB-1 promoter sequences across 
different species, revealed multiple transcription factors binding 
sites, such as those for AML-1, REL and Hunchback  
(Reference).  
In the human YB-1 promoter binding sites for MAX, ARNT, and 
FOS factors were identified using 90% stringency as the cut-off 
for this analysis. When the stringency was increased to 100% 
only N-Myc and Snail were predicted to regulate the YB-1 
promoter. The three members of the Myc family, C, N and L-
Myc, play important roles in the regulation of cell growth as 
transcriptional activators when dimerized with MAX. Snail 
belongs to a superfamily of zinc-finger transcriptional 
repressors that bind to a six base sequence, CAGGTG, known 
as the E-box (Batlle et al. 2000). It is involved in cell movement 
during embryogenesis and has been implicated in promoting 
epithelial mesenchymal transition (EMT). EMT phenotype 
arises from the suppression of E-cadherin by Snail resulting in 
the loss of contact between neighbouring cells (Batlle et al. 
2000; Cano et al. 2000). Conversely, Snail over-expression can 
promote recurrence of primary breast tumors in mice and is 
associated with decreased patient disease-free survival time in 
all patient groups (Moody et al. 2005).  
YB-1 is also regulated post-translationally. Many transcription 
factors are indeed regulated by Receptor Tyrosine Kinase 
(RTK) signal transduction.  
Does YB-1 works downstream to the RTK signalling to promote 
tumor growth and/or resistance to therapy? This remains still an 
open question. 
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2. Aims of the work  
 
Increasing evidences associate ΔNp63α dysregulation with 
squamous cell carcinomas (SCCs) (Fukunishi et al., 2010). On 
the other hand, loss of ΔNp63α expression was found to be 
involved in tumor progression and metastasis supporting the 
idea that ΔNp63α plays a relevant role as a suppressor of 
metastases (Graziano et al., 2011; Adorno et al., 2009). In 
addition, downregulation of ΔNp63α by Snail transcription 
factor, was found to reduce cell-cell adhesion and increase the 
migratory properties of squamous carcinoma cells 
(Higashikawa et al., 2007).  
To shed light on the role of p63 in epithelial cancer, I focused 
my work on the study of the interaction between Np63 and 
the YB-1 oncoprotein, a newly identified Np63 partner, that is 
already known to be an important marker of tumorigenesis in 
several malignancies (Sutherland et al., 2005).  
My work consists of four distinct phases: 
 
I. Study of the interaction between p63 isoforms and YB1 using 
in vivo and in vitro approaches. Determination of the mutual 
effects on the expression levels, stability and sub-cellular 
localization.  
 
II. Analysis of the effects of p63 and YB-1 on PI3KCA gene 
transcription and ability of YB-1 to bind specific mRNA into the 
cytoplasm.  
 
III. Determination of the effect of p63 on the ability of YB-1 to 
promote cell migration in tumor cells. 
 
IV. Analysis of YB-1 and p63 gene expression in primary cells 
and regenerating corneal tissue.  
 
The final aim of this work is to support relevant knowledge to 
develop new pharmacological agents and therapies that 
impinging on YB-1 and/or Np63 changes during cancer 
progression can help to fight tumor progression. 
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3. RESULTS 
 
3.1 Analysis of Y-Box Binding Protein 1 expression in 
different cancer cell lines. 
 
In the laboratory where I’ve carried out my PhD thesis, a 
comprehensive screening for ΔNp63α interactors was 
performed using functional proteomics. Through this approach 
a total of 53 potential Np63 binding partners were identified. 
Proteins with DNA/RNA binding activity were highly represented 
and the Y-Box binding protein 1 (YB-1 or YBX-1) was one of 
them (Amoresano et al., 2010). Figure 3 shows a graphic 
representation of p63 potential interactors grouped on the basis 
of their function. 
 
 
 
I first analyzed the expression profile of YB1 in a set of different 
cancer cell lines. YB-1 was abundantly expressed in all cell 
lines tested. Immunoblot analysis of total cell extracts using 
antibodies against the N-terminus of YB-1 showed a series of 
immunoreactive bands with an apparent molecular weight of 50 
(YB-1-50), 43 (YB-1-43) and 36 KDa (YB-1-36) (Figure ).  
As previously reported, different proteolytic forms of YB-1 show 
a different subcellular localization (reference). Therefore, using 
a protocol for nuclear/cytoplasmic cell extract fractionation, 
Figura 3 The p63 interactors . Schematic representation of p63 interactors isolated by co-
immunoprecipitation and subsequent analysis by mass spectrometry 
[Digitare il testo] 
 
49  
 
based on the use of a linear gradient of sucrose, I separated 
the nuclear and cytoplasmic fractions of YB-1. Immunoblot 
analysis was then performed using antibodies against the N-
terminal region of YB1. Depending on the cell line, I found 
considerable differences in the electrophoretic pattern of YB-1 
immunoreactive bands not only respect to their relative 
abundance but also to their distribution between the nuclear 
and cytoplasmic compartments. 
 
 
 
 
 
 
By treating cells with the proteasome inhibitor MG132, the YB-
1-43 and YB-1-36 bands disappeared while YB-1-50 
accumulated, thus suggesting that the smaller forms of YB-1 
were due to specific proteolityc cut (Figure 5). The experiment 
also shows that p53 enforced expression does not significantly 
changes the YB-1 electrophoretic pattern in this cell context  
Figura 4 (a) Total cell extracts(20 g) from the indicated cell lines were subjected to Immunoblot  analysis 
using antibodies against the N-terminal region of YB-1. Actin was used as loading control (b;c) Nuclear or 
cytoplasmic extracts (20μg) from the indicated cell lines were separated by SDS PAGE and subjected to 
immunoblot. Proteins were detected with antibodies against the N-terminal region of YB-1, as indicated. 
(d) Nuclear or cytoplasmic extracts (30 to 40 μg)from U2OS and Saos2 cells were separated by SDS PAGE 
and subjected to immunoblot using a  polyclonal antibody against the full length YB-1 protein. PARP and 
pAKT were used as nuclear and cytoplasmic control respectively to check for cross-contamination. Images 
were acquired with CHEMIDOC (BIORAD) and analyzed with the Quantity-ONE software. 
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Figura 5 YB-1 immunoreactive protein bands are the results of specific proteolityc cuts. 
Untreated, mock or p53-transfected  (5-8 g of p53 expression plasmid) Saos2 cells were grown in cell 
culture medium supplemented or not with MG132. 24h after transfection, cell extracts were 
fractionated to obtain cytoplasmic and nuclear fractions. Nuclear and cytoplasmic extracts (20μg) were 
separated by SDS PAGE and subjected to immunoblot. Proteins were detected with anti-YB-1 antibody. 
Parp was used as nuclear control to check for cross contamination. Actin was used as loading control. 
 
3.2 YB-1 interacts with ΔNp63α in vitro and in vivo. 
 
To confirm the interaction between p63 and YB-1 have 
performed reciprocal co-immunoprecipitation experiments in 
HaCaT cell, expressing high levels of endogenous Np63 and 
p63 transfected H1299 cells that normally lack both p63 and 
p53. As shown in Figure 6, YB-1-50 was efficiently 
immunoprecipitated with p63 specific antibodies in both cellular 
contexts. However, as we could not observe ΔNp63α/YB-1 
immunocomplexes performing the reciprocal experiment 
(Figure 6b), we transfected HaCaT cells with a plasmid 
encoding the Flag epitope fused to YB-1. As shown in Figure 6c 
ΔNp63α was immunoprecipitated with anti-Flag antibodies, only 
in cells expressing Flag-YB1. To determine if the interaction can 
occur with other p63 isoforms we transfected H1299 cells with 
the p63 or  isoforms both in the TA or N version to perform 
co-immunoprecipitation experiments. Remarkably, I found YB-1 
present in immunocomplexes with α isoforms (left panel) but not 
γ (right panel). So we argued that YB-1 interacts with the p63 -
specific SAM or post-SAM domain. 
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Figura 6  ΔNp63α interacts with YB-1. (a) Extracts from HaCaT cells were immunoprecipitated 
with anti-p63 (a) or anti-YB-1 antibodies (b) and the immunocomplexes were blotted and probed with 
anti-YB1 or anti-p63 antibodies, as indicated. A sample with no antibody (no Ab) or irrelevant α-
mouse antibodies were included as controls. (c) Extracts from untransfected and 3XFlag-YB-1 (0.5 
μg) transfected HaCaT cells were immunoprecipitated with anti-Flag antibodies. The 
immunocomplexes were blotted and probed with anti-p63 (upper panel) or anti-YB-1 antibodies 
(lower panel). Anti-p53 was included as positive control of interaction (right pannel)  
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The co-immunoprecipitation assay by itself does not allow to 
determine  whether the association between two proteins is 
direct or mediated by other proteins. To address this point, I 
expressed YB-1, Np63and Np63 recombinant proteins in 
bacteria. After the purification procedure, the proteins were 
subjected to Far Western, an in vitro interaction assay.  
ΔNp63 and  cDNAs from the pcDNA3myc plasmid backbone 
were subcloned into the pRSETA bacterial vector under the 
control of T7 promoter.  This plasmid also encodes a sequence 
of polihistidine (His-tag) for protein purification. 
E. Coli DH5α strain was transformed with pRSETA-ΔNp63γ, 
pRSETA-Np63 and pRSETA-YB1 for plasmid amplification. 
Finally, the purified p63 and YB-1 encoding plasmids were 
transferred to E. coli BL21 (DE3) strain for IPTG-inducible 
protein expression. Bacterial extracts were then analysed for 
recombinant p63 or YB-1 protein expression. Upon induction 
with 1mM IPTGNp63 and  proteins were present in the 
supernatant of cells (Figure 8) while YB-1 formed inclusion 
bodies. Therefore, an additional His-tag affinity chromatography 
step was necessary to purify YB-1. The quality of the purified 
proteins was checked by reciprocal western blot experiments 
using anti-hys, anti-YB1 or anti-p63 antibodies. 
 
 
 
 
 
 
Figura 8 Analysis of expression of Np63 and YB-1 recombinant proteins:  BL21 AI cells of E. 
coli strain transformed with vectors pRSETA Np63a) or YB-1 (b) were grown in the LB medium at 0.2 
O.D. and then induced with 1mM IPTG. 1mL of cell growth was lysed and 10g of supernatant (a) or 
pellet (b) for each point were analyzed by SDS-PAGE followed by Western blot analysis with anti-p63 or 
anti-YB-1 antibodies. 20g of U2OS cell extract were included as control. 
a b 
Figura 7 YB1 interacts with  but not with  isoforms of p63. (a) H1299 cells were 
transiently transfected with ΔNp63α or TAp63 plasmid (5 μg) and GFP-tagged ΔNp63γ or 
TAp63 expression vectors. At 24 hrs, equal amount (1 mg) of extracts were immunoprecipitated 
with anti-p63 or anti-GFP antibodies. The immunocomplexes were blotted and probed with anti-
p63 and anti-YB-1 antibodies. A sample with no antibody (no Ab) were included as negative 
controls. 
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Then I performed a Far-Western blotting using ΔNp63α, 
ΔNp63γ or YB-1 recombinant proteins. Increasing amounts of 
proteins were subjected to SDS-PAGE and transferred to PVDF 
membranes. Proteins were quickly denatured using 6M urea 
and re-natured gradually allowing them to regain their native 
conformations. The filters were then incubated with appropriate 
amounts of the potential protein-partner which was used as a 
probe. After extensive washing, the filters were subjected to 
immunoblot with antibodies directed against the protein-probe. 
As shown in Figure X a, b, I found that YB-1 interacts with p63 
when ΔNp63α, but not ΔNp63γ, was used as a probe. I 
confirmed this result by performing the reciprocal experiment 
(Figure 9) 
 
 
 
 
 
Figura 3 Far-western analysis. (a) The indicated amount of purified recombinant YB-1, and BSA were 
subjected to SDS-PAGE, transferred to PVDF membrane and probed with 0.8 μg/ml of recombinant 
ΔNp63γ (left panel) or ΔNp63α (right panel). The membrane was washed and subjected to immunoblotting 
towards p63 antibodies followed by ECL. Recombinant ΔNp63α or ΔNp63γ (100 ng) were used as positive 
controls. Correct loading of the proteins was monitored by coomassie staining; m.w. (molecular weight 
markers). (b) The indicated amounts of purified recombinant ΔNp63α, ΔNp63γ, YB-1 and BSA were 
subjected to SDS–PAGE and transferred to PVDF membrane. The membranes were incubated with purified 
recombinant YB-1. The filter was incubated with anti-YB1 antibodies, washed and subjected to 
immunoblotting towards YB-1 followed by ECL detection. 
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3.3 p63 and YB-1 functional association: do they 
exert a reciprocal control on their expression 
levels?  
 
A physical association between two proteins can potentially 
influence their expression levels by several distinct mechanisms 
(review reference). I investigated  whether p63 enforced 
expression was able to modulate YB-1 protein levels and vice-
versa. H1299 cells were transfected with increasing amounts of 
vectors encoding TAp63,TAp63, Np63 or Np63. After 48 
hours, cell extracts were prepared and analysed by 
immunoblot. As shown in Figure 10, p63 over-expression did 
not significantly alter YB-1 expression levels.  I obtained similar 
results in different cancer cell lines.  
 
Figura 10 The p63 enforced expression does not induce significant changes of YB-1 
expression levels:  or 
p63 expression plasmids or pcDNA3 control vector (mock). Cell extracts were prepared and analysed 
by Western blot using anti-p63 or anti-YB-1 antibodies.  No substantial effects of p63 on the expression 
level of endogenous YB-1 were detectable. Actin was used as a loading control. 
 
An alternative approach to determine whether p63 exerts a 
control on YB-1 expression level was to knock-down p63 
expression in HaCaT and Fadu cells, expressing high levels of 
endogenous p63. As shown in (Figure 11, a) YB-1 was only 
slightly reduced in cells transfected with p63 siRNA. Using a 
similar approach, I did not detect significant changes of Np63 
expression level in HaCaT cells partially depleted of YB-1 by 
siRNA. (Figure 11, b)  
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Figura 11  Mutual effects of specific silencing: Hacat cells were treated with 25, 50 and 100nM 
p63 (a) or YB-1 (b) specific siRNA for 48h. 100nM siLUC were used as negative control (scrambled). 20g 
of cells lysates were separated by SDS PAGE and subjected to immunoblot. Proteins were detected with 
specific antibodies, as indicated. Actin was used as loading control 
 
3.4 ΔNp63α induces YB-1 nuclear accumulation  
 
YB-1 shuttles between the nucleus and cytoplasm exerting 
different and sometimes conflicting role in either cellular 
compartments (Ken Matsumoto, Alan P Wolffe 1998). In normal 
cells, however cytoplasmic YB-1 is largely prevalent. On the 
other hand, p63 is a transcription factor that localizes 
predominantly into the nucleus. However, in particular 
conditions, p63 immunoreactive stain was detected into the 
cytoplasm of breast epithelial cells (Bratthauer GL 2005).  
We wanted to address whether or not p63 was able to influence 
YB-1 subcellular localization and colocalize with YB-1 in the 
same subcellular compartment. 
To this aim, I performed immuno-localization assays in H1299 
cells. To avoid background problems, I decided to use direct 
fluorescence on YB-1-GFP transfected cells as YB-1 is highly 
and constitutively expressed in all mammalian cells.  
As shown in Figure 12., the large majority of cells transfected 
with YB-1-GFP showed a strong fluorescence signal in the 
cytoplasm (95%) while in the remaining (5%) the signal was 
distributed between the nucleus and cytoplasm (Figure 3b). 
Interestingly, Np63 transfected cells showed a significant 
increase in the number of cells showing YB-1GFP exclusively 
nuclear or equally distributed between the nucleus and 
cytoplasm.   
In particular, more than 40% of cells showed intense nuclear 
GFP signal (Figure  13a upper panel and 13b left panel), an 
additional 20% exhibited YB-1-GFP almost equally distributed 
between the nucleus and cytoplasm while the remaining 40% 
exhibited cytoplasmic GFP-YB1 (Figure13c). Conversely, YB-1-
GFP subcellular distribution was almost unaffected by ΔNp63γ 
expression (Figure13a lower panel and 13b right panel). The 
graph in the figure was obtained by counting 102 cells for each 
experimental point and classifying them on the basis of YB1-
GFP localization: cytoplasmic, nuclear-cytoplasmic, exclusively 
nuclear. Similar data were obtained using the YB-1 Flagged 
protein meaning that the GFP epitope does not alter YB-1 
cellular distribution. 
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Figura 4 Np63 induces YB-1 nuclear accumulation: H1299 cells were seeded in at 60% 
confluency (2.3 x 105) on 24 x 24 mm sterile coverglasses placed in 60 mm dishes and transiently 
transfected with GFP-YB1 expression vector (0.3 μg) alone (a)  or  with 1 μg of ΔNp63α expression 
vector (b). Cells were fixed and subjected to indirect immunofluorescence as indicated in Materials and 
Methods. GFP-YB1 was detected by direct fluorescence and p63 by using anti-p63 antibodies and 
secondary anti-mouse Cy3-conjugated (red). 4′,6-Diamidino-2-phenylindole (DAPI) was used to stain 
nuclei (blue). YB-1 GFP/DAPI merged image were generated with Adobe Photoshop CS3 software.  
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Given the importance of YB-1 and p63 deregulation in breast 
cancer progression (Huang et al., 2005), I queried if ΔNp63α 
was able to cause YB-1 nuclear translocation and accumulation 
in breast cancer cells. MDA-MB-231 is a cell line derived from 
aggressive, basal-like breast carcinoma (BLBC) expressing 
high level of endogenous YB-1, but no detectable p63. I 
transiently transfected ΔNp63α in these cell lines and detected 
Figura 13 ΔNp63α induces YB-1 nuclear accumulation. (a and b) H1299 cells were seeded in at 
60% confluency (2.3 x 105) on 24 x 24 mm sterile coverglasses placed in 60 mm dishes and transiently 
transfected with GFP-YB1  (0.3 μg) and 1 μg of ΔNp63α or ΔNp63γ expression vectors. Cells were fixed 
and subjected to indirect immunofluorescence as indicated in Materials and Methods, GFP-YB1 was 
detected by direct  while  p63 was detected using anti-p63 antibodies and secondary anti-mouse Cy3-
conjugated (red). Merge between p63 and GFP-YB1 are indicated by yellow arrows. 4’,6-Diamidino-2-
phenylindole (DAPI) was used to stain nuclei. Both ΔNp63α and ΔNp63γ exhibit nuclear localization. But 
only ΔNp63α determines YB-1 nuclear accumulation . (c) Plot showing the percentage of nuclear (white 
plot), nucleo-cytoplasmic (grey) and cytoplasmic (dark grey) GFP-YB-1. Each experimental point is the 
average of counts performed on 100 cells in 5 independent fields.  
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endogenous YB1 by indirect-immunofluorescence. As shown in 
Figure 14, intense staining of endogenous YB-1 was present in 
the nucleus of more than 90% of cells expressing ΔNp63α 
(Figure 14, yellow arrows).  
 
 
 
Figura 14 ΔNp63α induces nuclear accumulation of endogenous YB-1 in breast cancer cells. 
MDA-MB-231 cells were seeded at 60% confluency (2.3 x 105) on 24 x 24 mm sterile cover-glasses 
placed in 60 mm dishes and transiently transfected with 1 μg of ΔNp63α expression vector. Cells were 
fixed and subjected to double indirect immunofluorescence using rabbit primary YB-1 antibody and 
Fitch-conjugated secondary antibodies (green). P63 protein was detected using mouse anti-p63 and 
Cy3-conjugated secondary antibodies (red). 4’,6-Diamidino-2-phenylindole (DAPI) was used to stain 
nuclei (blue). More than 90% of cells expressing ΔNp63α showed nuclear YB-1 (yellow arrows). 
Cytoplasmic YB-1 was detected in cells bearing low or no ΔNp63α expression (white arrows). 
Then, I transfected FLAG-YB-1 construct alone or with Np63 
plasmid in MCF7 cells, derived from non aggressive basal-like 
breast carcinoma (BLBC). In MCF7 cells, FLAG-YB-1 was 
prevalently located in the cytoplasm. However, similar to what 
observed in MDA-MB-231 cells, FLAG-YB-1 was nuclear in 
almost all cells expressing detectable levels of Np63Figure 
15.
 
a 
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Figura 5 ΔNp63α induces nuclear accumulation of Flag YB-1 in breast cancer cells. (a) MCF7 
cells were seeded at 60% confluency (2.3 x 105) on 24 x 24 mm sterile coverglasses placed in 60 mm 
dishes and transiently transfected with 0,3 μg of FLAG YB-1 expression vector. Cells were fixed and 
subjected to double indirect immunofluorescence using anti-Flag antibody and secondary anti-rabbit 
Fitch-conjugated (green). The FLAG YB-1, as GFP YB-1 and endogenous YB-1,  exhibits a predominantly 
cytoplasmic localization. (b) MCF7 cells (2.3 x 105) were seeded as described in (a) and transiently 
transfected with Flag YB1 (0,3 g) and a fixed amount of pcDNA3/ΔNp63α expression vectors (1μg). 
Cells were fixed and subjected to double indirect immunofluorescence using anti-Flag antibody and 
secondary anti-rabbit Fitch-conjugated (green) P63 protein was detected using mouse anti-p63 and Cy3-
conjugated secondary antibodies (red). 4’,6-Diamidino-2-phenylindole (DAPI) was used to stain nuclei 
(blue). More than 90% of cells expressing ΔNp63α showed nuclear YB-1 (red arrows).  
To confirm the observed effect of Np63on YB-1 nuclear 
accumulation, using a different experimental approach, I 
performed  nuclear/cytoplasmic fractionation of extracts from 
MDA-MB-231 cells transfected with ΔNp63α or ΔΝp63γ. By 
immunoblot with antibodies against the YB-1 N-terminal region, 
YB-1 was detectable as 50 and 36 kDa immunoreactive bands. 
YB-1/50 kDa was present both in nuclear and cytoplasmic 
fractions while YB-1/36 kDa was detectable only in the nuclear 
fraction (Figure 16a). However, in cells transfected with 
ΔNp63α, but not ΔΝp63γ, we observed an increase of nuclear 
YB-1 (Figure 16a).  
Similar results were obtained in U2OS cells, expressing wild 
type p53, (Figure 16d) and in a p53-null context such as in 
Saos2 and H1299 cells, where co-transfection of Np63 
caused the nuclear accumulation of endogenous YB-1 and 
transfected Flag-YB-1 (Figure 16 b and c). 
Interestingly, I repeatedly observed an increase of the signal 
corresponding to phosphoserine at position 473 of Akt1 in the 
cytoplasm of ΔNp63α, but not ΔNp63γ, transfected cells 
suggesting that ΔNp63α was, in some way, involved in the 
activation of PI3K/Akt signalling (Figure 16 a and b). 
 
b 
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Figura 16 ΔNp63α, but not ΔNp63γ promotes YB-1 nuclear accumulation. MDA-MB-231 cells 
were transiently transfected with a fixed amount (5 μg) of an empty vector (mock), ΔNp63α or ΔNp63γ 
expression vector in 100 mm dishes. 24h after transfection, cell lysates were fractionated to obtain 
cytoplasmic and nuclear fractions. 20μg of nuclear and cytoplasmic extracts were separated by SDS PAGE 
and subjected to immunoblot. Proteins were detected with specific antibodies, as indicated. PARP and total 
AKT were used as nuclear and cytoplasmic control respectively, to check for cross-contamination. Images 
were acquired with CHEMIDOC (BIORAD) and analyzed with the Quantity-ONE software. SAOS2      cells(b) 
and H1299 cells(c) were transfected with an empty vector and a fixed amount of pEGFP/YB-1 encoding 
plasmid alone or with ΔNp63α plasmid. After subcellular fractionation, 20 μg of protein extract were 
subjected to immunoblot with the indicated antibodies. (d) U2OS cells were transfected with an empty 
vector and a fixed amount of pFlag/YB-1 encoding plasmid alone or with ΔNp63α plasmid. After subcellular 
fractionation, 20 μg of protein extract were subjected to immunoblot with the indicated antibodies. PARP 
and pAKT were used as nuclear and cytoplasmic control respectively was used as nuclear control, to check 
for cross-contamination. Actin was used as loading control. 
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3.5 Role of Akt in ΔNp63α-mediated YB-1 nuclear 
translocation 
 
Akt/PKB is a serine/threonine kinase that promotes tumor cell 
growth by phosphorylating transcription factors and cell cycle 
proteins. YB-1 is a phospho-substrate for Akt. The major site 
phosphorylated by Akt on YB-1 was mapped to Serine 102 and 
disruption of this residue was correlated with inhibition of YB-1 
nuclear translocation (Sutherland et al., 2005; Evdokimova et 
al., 2006). Because of the ability of ΔNp63α to trigger Akt 
phosphorylation, we looked at the effect of Akt activation in YB-
1 nuclear accumulation. We co-transfected YB-1GFP with 
activated Akt (CAAkt) (Rao et al., 2005). As shown in Figure 8a, 
upon intense Akt activation, the YB-1GFP fluorescence signal 
appeared to be reduced and confined to the perinuclear 
compartment. However, when CA-Akt was cotransfected with 
ΔNp63α, the whole number of cells showing intense GFP-YB1 
nuclear signal also expressed ΔNp63α while cells showing 
perinuclear GFP-YB1 expressed a barely or not detectable level 
of ΔNp63α (Figure 17).  
 
 
 
 
 
Figura 17 Akt activation does not promote, by itself, YB1 nuclear accumulation. H1299 
cells, seeded at 60% confluency (2.3 x 105) on a 24 x 24mm steryl coverglass in 60mm dishes, were 
transiently transfected with GFPYB-1 (0,3 μg) plasmid alone or with CA-Akt1 (1 μg) with or without 
ΔNp63α plasmid  (1 μg), as indicate in figure, Cells were fixed and subjected to direct 
immunofluorescence. P63 protein was detected using mouse anti-p63 and Cy3-conjugated 
secondary antibodies (red) 4′,6-Diamidino-2 phenylindole (DAPI) was used to stain nuclei (blue). 
Merge was generated by Adobe Photoshop CS3 software. 
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Like the wild type, the phosphorylation-defective FlagYB-
1S102Adid not  translocate to the nucleus when cotransfected 
with CA-AKT. However, it was equally able to accumulate into 
the nucleus in cells expressing Np63 (Figure 18) suggesting 
that phosphorylation of this residue was not required for 
Np63-mediated YB-1 nuclear accumulation.  
 
 
 
Figura 18 Akt activation does not promote, by itself, YB1S102A nuclear accumulation. (a) 
2.3 x 105 MCF7 breast carcinoma cells were seeded on a 24 x 24mm steryl coverglass in 60mm dishes 
and were transiently transfected with FlagYB-1S102A  plasmid alone (0,3 μg, left panel) or with CA-Akt1 
plasmid (1 μg, right panel), as indicated in figure. Cells were fixed with PFA and processed for indirect 
immunofluorescent with rabbit anti-flag antibody and secondary Cy3-coniugated rabbit antibodies 
(green). DAPI counterstain (blue) indicates the location of nuclei and merged images were generated 
using Adobe Photoshop CS3 software. (b) MCF7 cells  were seeded at 60% confluency (2.3 x 105) on 24 x 
24 mm sterile coverglasses placed in 60 mm dishes and transiently transfected with 1 μg of Flag YB1-
S102A and a fixed amount of pcDNA3/ΔNp63α expression vectors (1μg) expression vectors. Cells were 
fixed and subjected to double  indirect immunofluorescence as indicated in Materials and Methods, 
using anti-Flag antibody and secondary anti-rabbit Fitch-conjugated (green). p63 was detected using 
anti-p63 antibodies and secondary anti-mouse Cy3-conjugated (red). Merge between DAPI and Flag-YB1 
S102A are indicated. 4’,6-Diamidino-2-phenylindole (DAPI) was used to stain nuclei.  
 
a 
b 
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Finally, I observed that compared to the wild type or the 
FlagYB-1S102A protein, the phospho-mimetic FlagYB-1S102D 
mutant was expressed at lower level (Figure 19). This 
suggested that instead to promote nuclear accumulation, 
phosphorylation of Serine 102 by AKT was affecting YB-1 
protein stability.  Accordingly, as detected by western blot 
analysis, CA-AKT expression reduced the abundance of both 
wild type and FlagYB-1S102A protein thereby suggesting that 
AKT can decrease YB-1 stability by phosphorylating multiple 
phospho-acceptor sites of YB-1. Consistently, the fluorescent 
signal corresponding to the FlagYB-1S102D mutant was hardly 
detectable in cells transfected with CA-AKT (Figure19). 
Conversely, this mutant gave a strong nuclear fluorescent 
signals in Np63 positive cells.  
 
 
Figura 19: Akt activation does not promote, by itself, YB1S102D nuclear accumulation. 2.3 x 
105 MCF7 breast carcinoma cells were seeded on a 24 x 24mm steryl coverglass in 60mm dishes and 
were transiently transfected with FlagYB-1S102D  plasmid alone (0,3 μg, left panel) or with CA-Akt1 
plasmid (1 μg, right panel), as indicated in figure. Cells were fixed with PFA and processed for indirect 
immunofluorescent with rabbit anti-flag antibody and secondary Cy3-coniugated rabbit antibodies 
(green). DAPI counterstain (blue) indicates the location of nuclei and merged images were generated 
using Adobe Photoshop CS3 software. (b) MCF7 cells were seeded at 60% confluency (2.3 x 105) in 
60mm dishes and transfected with wild type FlagYB-1 or FlagYB-1S102A (0,3 μg) plasmid alone or with 
CA-Akt1 (1 μg) or ΔNp63α plasmid (1 μg). Total cells extracts, separated in 10% polyacrilammide gel, 
were analyzed by immunoblot using the indicated antibodies. Actin was used as loading control. (c) 
MCF7 cells  were seeded at 60% confluency (2.3 x 105) on 24 x 24 mm placed in 60 mm dishes and 
a 
b 
c 
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transiently transfected with 1 μg of Flag YB1-S102D and a fixed amount of pcDNA3/ΔNp63α expression 
vectors (1μg). Cells were fixed and subjected to double  indirect immunofluorescence, using anti-Flag 
antibody and secondary anti-rabbit Fitch-conjugated (green). p63 was detected using anti-p63 
antibodies and secondary anti-mouse Cy3-conjugated (red). Merge between DAPI and Flag-YB1 S102A 
are indicated. 4’,6-Diamidino-2-phenylindole (DAPI) was used to stain nuclei.  
 
3.6 ΔNp63α influences YB1-protein turnover 
 
By immunoblot analyses I confirmed that the expression level of 
the phospho-mimetic mutant YB-1S102D (50 kD) was 
significantly lower compared to the wild type and YB-1S102A 
proteins. However, ΔNp63α enforced expression caused a 2.28 
folds increase of YB-1S102D protein abundance (Figure 20b) 
with a similar increase of its nuclear-cytoplasmic ratio (Figure 
20 c and d).  
 
 
 
Figura 20 ΔNp63α increase YB-1 nuclear fraction. (a) MCF7 cells, seeded at 60% confluency (2.3 x 
105) in 60mm dishes, were transiently transfected with vector expressing wild type FlagYB-1, S102A or 
S102D mutants (0.3 μg each). Equal aliquots of total cell lysates (10 μg) were separated in 10% SDS-
PAGE and subjected to immunoblot with anti-Flag polyclonal antibody. Actin was used as a loading 
control (b) Plots showing the expression of total wild type, S102A or S102D FlagYB-1 proteins with or 
without p63. Data were obtained by densitometry scanning of immunoblot revealed with anti-Flag 
antibodies and normalized to actin expression. Values are mean±S.D. of three independent experiments 
(c) 5 x 106 MCF7 cells, seeded in 100mm dishes, were electropored with 2 μg of each vector expressing 
wild type FlagYB-1, S102A or S102D mutants with or without 4 μg of ΔNp63α plasmid. At 24h from 
transfection nuclear and cytoplasmatic extracts were prepared as indicated in Materials and Methods, 
analysed by 10% SDS-PAGE and subjected to immunoblot with the indicated antibodies. Total Akt and 
PARP antibodies were used as cytoplasmic/nuclear loading and quality control. (d) Plots showing the 
average value of YB-1 protein nuclear/cytoplasmic ratio obtained by densitometric scanning of 
immunoblot with anti-Flag antibodies. Both cytoplasmic and nuclear extracts were first normalized for 
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actin loading control. For each value the average of five different exposures was calculated and each 
value was normalized against total AKT and PARP for cytoplasmic and nuclear extracts, respectively. 
 
 
These preliminary observations prompted us to further 
investigate about the effect of Np63 on YB-1 protein stability.  
Therefore, we measured YB-1 protein half-life in mock and 
ΔNp63α transfected MDA-MB-231 cells, by treating cells with 
cycloheximide (CHX). As shown in Figure 21, the rate of decay 
of endogenous YB1 follows a biphasic pattern: an initial phase 
in which YB1 decays rapidly (half-life of about 2 hrs) is followed 
by a latter phase in which the YB1 protein level remains 
substantially unchanged.  
Next, I measured YB-1 protein half-life in ΔNp63α transfected 
cells and I found that the initial phase, characterized by rapid 
YB-1 protein degradation, was strongly reduced.  
In agreement with our results with transfected p63, the rate of 
decay of endogenous YB-1 in HaCaT cells, expressing  
endogenous ΔNp63α, was remarkably slower than in H1299 
cells lacking p63, thereby indicating that it was not an artifact of 
transient ΔNp63α over-expression (Figure 21b).  
Finally, I measured YB-1 protein half-life, by cycloheximide 
decay, in nuclear and cytoplasmic fractionated extracts. 
Compared to cytoplasmic YB1, the nuclear protein had a 
significantly reduced rate of turnover (Figure 21c and d).  
All together, these observations suggest that the nuclear pool of 
YB-1 protein is more stable than the cytoplasmic one and 
ΔNp63α appears to increase the nuclear, slow degrading pool 
of YB-1. 
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3.7 ΔNp63α and YB-1 nuclear functions 
 
YB-1 directly interacts and activates the promoter of PIK3CA 
gene, encoding the p110α catalytic subunit of 
phosphatidylinositolo-3-kinase, thereby increasing PI3K/Akt 
activity (Astanehe et al., 2009). Accordingly, YB-1 depletion in 
MDA-MB-231 cells resulted in a reduction of Akt1 
phosphorylation (Figure 22, left).  
 
 
 
As we noticed that enforced expression of ΔNp63α caused a 
dose dependent enhancement of Akt1 phosphorylation (Figure 
22, right), we monitored the response of PIK3CA gene promoter 
to ΔNp63α, by luciferase assays (see materials and methods).  
Figura 6 ΔNp63α influences YB-1 protein turnover. (a) At 16 hrs, 20 μM cycloheximide (CHX) was 
added to mock and ΔNp63α transfected MDA-MB-231 cells. At the indicated times, cell were harvested and 
equal amounts of protein extracts were subjected to immunoblot with anti-YB-1 antibodies. Data from 
densitometric scanning were normalized against actin and plotted (YB-1, dotted line; YB-1 + p63, continuos 
line). Standard deviations from 3 independent experiments are indicated by error bars. (b) H1299 cells 
(devoid of p63, left panel) and HaCaT cells (expressing abundant endogenous ΔNp63α, right panel) were 
seeded at 60% confluence (2.3 x 105) in 60mm dishes and treated with 20 μM CHX, for the indicated times. 
Equal amounts of extracts were subjected to immunoblot with anti YB-1 and anti p63 antibodies. Actin was 
used as loading control. (c) 3 x 106 MDA-MB-231 cells were seeded in 100mm dishes (60% confluency) and 
treated with 20 μM cycloheximide for the indicated times. Nuclear and cytoplasmic fractionated extracts 
(2,5 μg) were separated by SDS-PAGE and subjected to immunoblot with anti-YB-1 antibody. Total Akt and 
PARP antibodies were used as loading and quality control of cytoplasmatic or nuclear extracts, respectively. 
(d) Plots showing the rate of decay of cytoplasmic and nuclear YB-1 as obtained by densitometry scanning. 
Data were obtained as the average of five different exposures and each value was normalized to the 
appropriate loading control ( Total-Akt or PARP). The relative values for cytoplasmatic and nuclear YB-1 
protein distribution were calculated by placing equal to one the expression of cytoplasmatic and nuclear 
YB-1 at time 0. The data are from three independent experiments and the standard deviation are indicated 
by error bars. 
 
Figura 7 ΔNp63α controls YB-1 nuclear function. (left) MDA-MB-231 cells were transfected with 
25nM of siRNA to YB-1 and scrambled control or (right) with increasing amounts of pcDNA3/ΔNp63α 
encoding plasmid. 48hr after transfection, cells were lysate and 20μg of total extract were subjected to 
Western Blot analysis and immunorevealed with anti-total AKT, pAKT or anti-YB-1. 
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As shown in Figure 23, ΔNp63α enforced expression caused a 
significant increase of the PIK3CA promoter activity that was 
attenuated by YB-1 knock-down. 
 
 
Figura 8 MDA-MB-231 cells were transfected with 1μg of luciferase reporter construct containing 
PIK3CA promoter and luciferase activity was measured upon YB-1siRNA, ΔNp63α or ΔNp63α and YB-
1siRNA transfection. The results are reported as the average of at least three independent experimental 
points (left panel). Aliquots of duplicate samples assayed by Luciferase activity (20 μg) were subjected to 
immunoblot with the indicated antibodies (right panel) 
 
Next, we performed Chromatin IP (ChIP) in MDA-MB-231 cells 
transfected with Flag-YB1 with or without ΔNp63α to evaluate 
the binding of YB-1 to the PIK3CA promoter, a well known YB-1 
target (Astanehe et al., 2009). As shown in Fig 7d, ΔNp63α 
dramatically increased the binding of Flag-YB1 to the PIK3CA 
promoter. Next, ChIP was performed using antip63 (4A4) 
antibodies in cells transfected with ΔNp63α or ΔNp63γ and we 
found that ΔNp63α, itself, binds to the PIK3CA promoter 
whereas ΔNp63γ failed to do so (Figure 7e). 
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3.8 ΔNp63α affects YB-1 cytoplasmic functions 
 
Cytoplasmic localization of YB-1 was associated with binding 
and translational activation of Snail1 mRNA (Evdokimova et al., 
2009). By western blot experiment and semiquantitative RT-
PCR, I have shown that ΔNp63α, but not ΔNp63γ, reduced 
Snail1 protein level without changing the level of Snail1 
transcript (Figure 25 a and b). Interestingly, the level of Twist 
specific transcript, instead, appeared to be reduced by ΔNp63α 
expression (Figure 25 b).  
 
Figura 9 ΔNp63α affects YB-1 cytoplasmic functions. (left panel) MDA-MB-231 cells were transfected with an empty 
vector (mock) or a fixed amount (1μg in 60mm dishes) of pcDNA3/ΔNp63α or pcDNA3/ΔNp63γ expression vector. 24 hr after 
transfection, cells were harvested and total extracts were prepared. 20μg of each extract were loaded on SDS-PAGE and 
subjected to immunoblot with the indicated antibodies. (right panel) MDA-MB-231 cells were transfected with an empty 
vector or pcDNA3/ΔNp63α encoding plasmid. The expression level of ΔNp63α was checked by immunoblot (Figure 14a, left 
panel). 24hr after transfection total RNA was purified and retrotranscribed as described in Materials and Methods. PCR was 
performed with primers designed to specifically amplify Snail1, Twist or HPRT transcripts (see Materials and Methods). (b) 
Plot showing the level of Snail1 and Twist transcripts, normalized respect to HPRT. Values are the mean of 3 independent 
experiments. 
 
Figura 24 (a) MDA-MB-231 cells were seeded at 60% confluency (1.2 x 106) in 100mM dishes and 
transiently transfected with 3XFlag-YB-1 (5 μg) construct with or without ΔNp63α (2.5 μg) expression 
vector. The cells were cross-linked with formaldehyde and DNA/protein complexes were 
immunoprecipitated with anti-Flag antibody or irrelevant IG g antibody as negative control. The DNA 
immunoprecipates were analysed by qPCR using PIK3CA or GAPDH promoter oligos. qRTPCR results were 
analized with the ΔΔCT method and expressed as fold of enrichment respect to the IG g control samples. 
of each input. Values are represented as the mean of three independent experiments. (b) MDA-MB-231 
cells were seeded at 60% confluency (1.2 x 106) in 100mM dishes and transiently transfected with 
ΔNp63α or ΔNp63γ plasmid (5 μg). After formaldehide crosslinking, the DNA/proteins complexes were 
immunoprecipitated with anti-p63 (4A4) antibody. Immunoprecipitated DNA was PCR amplified with 
PIK3CA promoter oligos and 18S oligos. Input DNA (3% of total immunoprecipitate) was amplified to 
demonstrate that primers produced the expected PCR products ( upper panels). M.W. molecular weight 
DNA ladder. The data obtained from the ChIp assay were measured by densitometry and are presented as 
fold induction relative to the basal expression levels in the input (lower panel). Values are the mean of 
three independent experiments. 
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Next, I performed RNA-Immunoprecipitation to determine the 
amount of Snail1 mRNA bound to YB-1, and I found that it was 
significantly reduced in presence of ΔNp63α (Figure 26). 
Since Snail1 is known to be directly implicated in E-cadherin 
repression (Peirò et al., 2006), I checked the expression level of 
E-cadherin upon ΔNp63α enforced expression in MCF7 cells 
that express detectable levels of both E-cadherin and Snail1. 
As shown in Figure 26 (right panel), ΔNp63α caused a dose-
dependent increase of E-cadherin that was associated with a 
parallel reduction of Snail1. 
 
 
 
 
Finally, because it was reported that cytoplasmic YB-1 inhibits 
translation of its own mRNA, by specific interaction with the 
3’UTR (Skabkina et al., 2005), I tested the effect of ΔNp63α on 
the ability of YB-1 to bind to its own transcript, by RNA 
immunoprecipitation. Briefly, YB1-bound cytoplasmic RNA was 
immunoprecipitated with antibodies against YB-1. As shown in 
Figure 27, binding of YB-1 to its own transcript was 
substantially reduced in MDA-MB-231 cells expressing 
ΔNp63α. 
Figura 26 (left) Nuclear extracts from ΔNp63α transfected MDA-MB-231 cells were 
immunoprecipitated with anti-YB1 antibody. After reverse cross-linking the YB1-bound RNA was 
purified, retrotranscribed and subject to qRT-PCR analysis using oligonucleotides designed to specifically 
amplify Snail1 transcript. Plot represents the % of enrichment of Snail1 transcript normalized as 
indicated in Materials and Methods. 1/50 of the input extract was loaded as control. (right) MCF-7 cells 
were transfected with an empty vector or the indicated amount of pcDNA3/ΔNp63α plasmid. 24hr later, 
cell extracts were prepared and 30μg of each were loaded on SDS-PAGE and subjected to immunoblot 
with the indicated antibodies. Actin was used as loading control. 
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Figura 27 YB-1- bound RNA was obtained from mock or ΔNp63α transfected MDA-MB-231 cells by RNA 
immunoprecipitation. RNA was retrotranscribed and subjected to qRT-PCR using oligonucleotides 
designed to specifically amplify YB-1 transcript. Plot represents the % of enrichment of YB-1 transcript 
normalized respect to no-Antibodies sample. 
 
3.9 Effects of ΔNp63α and YB1 on cell migration 
 
Recent studies have provided convincing evidence that YB-1 
up-regulation drives epithelial to mesenchimal transition (EMT) 
that is associated with reduced proliferation, increased cell 
motility and invasiveness (Evdokimova et al., 2009). Since 
ΔNp63α affects YB-1-dependent transcription of pro-migratory 
genes such as Snail1, we hypothesize that it should also 
restrain the migratory ability of YB1 overexpressing cells. This 
aspect was addressed with the collaboration of prof. Netti group 
using genetically modified TetOn-H1299 cells expressing 
ΔNp63α upon Doxycycline (Dox) addition (Figure 28). Cells 
were transfected with GFP or GFP-YB1 plasmid and 
unfluorescent and fluorescent cells were tracked separately. 
Cells migrated describing trajectories that are randomly 
distributed in plane, as depicted in plots of Figure 28b. Root 
mean square speed (S) and persistence time (P) were 
computed from cell tracks and are a measure of the frequency 
of cell steps and of the minimum time that is necessary for a 
cell to significantly change direction. In Dox free medium (-Dox), 
GFP-YB1 expressing cells were characterized by a significantly 
higher S and lower persistence (0.69 ± 0.04 μm/min and 8.4 ± 
0.5 min) than cells expressing GFP alone (0.54 ± 0.05 μm/min 
and 15 ± 2.1 min). Remarkably, in Dox supplemented medium 
(+ Dox), GFP-YB1 expressing cells exhibited a S and P values 
(0.62 ± 0.5 μm/min and 9.2 ± 1.0 min), which were not 
significantly different from those of cells transfected with GFP 
alone (0.68 ± 0.05 μm/min and 8.6 ± 0.9 min). We also noticed 
that unfluorescent cells were characterized by the highest S 
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values suggesting that expression of the Green Fluorescent 
Protein alters cell migration to some extent (data not shown). 
However, S of unfluorescent cells with or without Dox was 
comparable. 
 
 
 
 
 
Figura 28 ΔNp63α counteracts YB-1 induced enhancement of cell migration. (a) Immunoblot 
analysis of ΔNp63α in H1299 cells treated (+ Dox) or not (- Dox) with Doxicycline. After migration analysis, 
cells extracts were prepared and subjected to immunoblot with the indicated antibodies to monitor 
ΔNp63α induced expression. (b) Trajectories of GFP/YB-1 or GFP (insets) transfected cells. Inducible 
H1299/ΔNp63α cells were transfected with a fixed amount of GFPYB1(1μg) or GFP empty vector (1μg). 4hr 
after transfection, 2 μg/ml of doxycycline was added to induce ΔNp63α expression and 16 hr later 
uninduced (-Dox) and induced (+Dox) cells were tracked with optical microscopy. Plots represent data from 
the following number of cell (YB-1/-dox 79; YB-1/+dox 69; control/-dox 44; control/+dox 49). (c) Bar chart 
of speed (S; grey bars) and persistence ratios (P; white bars). The ratios are computed by dividing the 
population average values of speed and persistence for H1299 cells treated (+ Dox) or not (- Dox) with 
Doxicycline. 
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3.9.1 Expression of p63α and YB-1 in resting and 
regenerating cornea 
 
We have previously shown that YB-1 and ΔNp63α are co- I 
have previously observed that YB-1 and ΔNp63α are co-
expressed in proliferating keratinocytes and both are 
downregulated during calcium-induced differentiation.  
In collaboration with Dr. Di Iorio of the ―Eye bank foundation‖, 
Zelarino, Venezia I have investigated the role of YB-1 and p63 
in normal and regenerating corneal tissues.  We have chosen 
the cornea because it is an interesting model to investigate the 
expression of both p63 and YB-1 markers during differentiation. 
Therefore, we speculated that a functional interplay between 
these two proteins may occur in basal proliferating 
keratinocytes of adult tissues or in regenerating epithelia, for 
instance after mechanical injury. The corneal regenerating 
epithelium provides a suitable model to follow the expression of 
YB-1 and p63 during transition between epithelial stem cells 
and terminally differentiated keratinocytes. Specifically, corneal 
stem cells are segregated in the basal layer of the limbus. 
When activated by mechanical injury, they produce Transit-
Amplifying (TA) cells that divide only a few times during their 
migration from the limbus to the central cornea where they 
terminally differentiate (Di Iorio et al., 2005). In unperturbed 
corneas, p63 is present only in patches of basal limbal stem 
cells while it is undetectable in the differentiated central corneal 
epithelium (Di Iorio et al., 2005). YB-1, instead, is expressed in 
limbus as well as in central cornea and is prevalently 
cytoplasmic (Figure 29a and b). In limbus of resting corneas, a 
lot of cells show overlap between ΔNp63α and YB-1 (Figure 
29a). Overlapping between YB-1 staining and CK12, a marker 
of corneal cell differentiation indicates that, unlike p63, 
cytoplasmic YB1 expression persists in differentiating corneal 
cells (Figure 29b). In activated cornea, where p63 decorates the 
nuclei of basal and suprabasal layers of limbal and central 
cornea, p63 and YB-1 colocalization was frequently detected 
and particularly in cells moving from the basal towards the 
suprabasal layers (Figure 29c). Of interest, at higher 
magnifications (63X), YB-1 signal was clearly localized either in 
the nucleus (highlighted with number) or in the cytoplasm, thus 
confirming previous data showing that YB-1has the capacity for 
continuous shuttling between the cytoplasm and the nucleus 
(Figure 30a). 
The expression of p63 is strongly correlated to cell size and it is 
expressed in a small amount of undifferentiated limbal stem 
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cells (holoclones) and progressively decreases during clonal 
conversion from holoclone to paraclone and serial in vitro 
propagation, in which a consistent increase of cell size is 
usually observed (Di Iorio et al., 2005). 
In samples of corneal primary cultures, corneal stem cells, the 
smallest ones, express p63 and YB-1 abundantly (Figure 30b, 
left panel), but after serial cultivation (after the fifth passage), 
the large and terminally differentiated corneal keratinocytes 
appeared to be devoid of both p63 and YB1 specific staining 
(Figure 30b,right panel, yellow asteriks). 
 
 
 
 
 
Figura 10 Expression of p63 and YB-1 in cornea. Double immunofluorescence of YB-1 (red) with (a) p63 
(green) on sections of resting limbus and with (b) cK12 (green) on sections of resting cornea. p63 and YB-1 
were coexpressed by a discrete number of basal cells (merge frame), but YB1 expression persisted in 
differentiating corneal cells, as shown by overlap con cK12. In activated limbus (c) and cornea (d), where p63 
decorates the nuclei of basal and suprabasal layers, p63 and YB-1 colocalization was frequently detectable and 
particularly in cells moving from the basal towards the suprabasal layer. 
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Figura 11: (a) Higher magnification (63X) showed nuclear localization of YB-1 in some cells, indicated by yellow asterisks. (b) 
Cytological detection of YB-1 (red) and p63 (green) in corneal primary cultures: note the high percentage (60%–70%) of cells in 
which p63 and YB-1 are coexpressed. (right panel) When corneal keratocytes were serially propagated in vitro, YB-1 expression 
was definitely lost in large and terminally differentiated cells indicated by asterisks. 
a 
b 
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4. Discussion 
 
 
My work unveils a novel protein-protein association involving 
ΔNp63α and YB-1 and a mechanism through which a factor 
essential for epithelial development and differentiation can 
control the activity of an oncoprotein. By in vitro and in vivo 
protein-protein interaction assays we have unequivocally 
demonstrated that the α-specific C-terminal region of p63 and 
the 36 kDa Nterminal fragment YB-1 are involved in such 
physical association. In malignant cells, overexpression and 
nuclear localization of YB1 is correlated with 
multidrugresistance and hyper-proliferation (Janz et al., 2002). 
In normal cells, instead, the majority of YB1 protein localizes to 
the cytoplasm, with a minor pool located into the nucleus.  
My data show that ΔNp63α enforced expression promotes YB-1 
nuclear accumulation and Akt phosphorylation (Sabbisetti et al., 
2009). In principle, p63-driven YB-1 nuclear accumulation could 
be considered as a consequence of Akt activation. However, as 
we have shown that exogenous expression of constitutively 
activated Akt (CA-Akt) did not result in YB-1 nuclear 
translocation, the physical interaction with ΔNp63α seems to be 
necessary for YB-1 nuclear targeting. Expression of CA-Akt, 
instead, appeared to cause a moderate reduction of the level of 
cytoplasmic YB-1 and its preferential re-distribution from a 
diffuse cytoplasmic to a perinuclear localization. These 
observations are in line with previous findings showing that 
PI3K/Akt signaling activation, instead of causing YB-1 nuclear 
localization, impairs the binding of YB-1 to cytoplasmic 
transcripts releasing their translational repression (Evdokimova 
et al, 2006). Furthermore, the phosphorylation defective YB-
1Ser102A protein, as the wild type and Ser102D mutant 
protein, colocalizes with ΔNp63α into the nuclear compartment 
thus indicating that disruption of the major phosphoacceptor site 
on YB-1 does not prevent YB1 nuclear translocation by 
ΔNp63α. 
Furthermore, we present evidences that Akt activation, rather 
than promoting YB-1 nuclear translocation, plays a role in the 
control of YB-1 protein turnover. In fact, we observed that wild 
type YB-1 as well as YB-1S102A protein level was reduced by 
CA-Akt thus suggesting that Akt targets multiple phospho-
acceptor sites, including Serine 102, thereby reducing YB-1 
protein stability. According to this hypothesis, we found that the 
phospho-mimetic YB1-S102D mutant was expressed at very 
low level. Moreover, by cycloheximide decay experiments, we 
have observed that nuclear YB1 protein displays a slow rate of 
turnover when compared to its cytoplasmic fraction. 
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Therefore, we suggest that ΔNp63α, by targeting YB-1 into the 
nucleus, increases the slow degrading component of YB-1. YB-
1 and ΔNp63α are both transcription factors, and a 
considerable number of their targets have already been 
identified (Jurchott et al, 2006). However, an intriguing point is 
whether the association between YB-1 and ΔNp63α can drive 
the complex on particular promoters. 
Remarkably, we show that the PIK3CA gene, a well 
characterized YB-1 target gene, is also regulated in vivo by 
ΔNp63α. ChIP analyses demonstrate that ΔNp63α binds to the 
PIK3CA promoter; it remains to be addressed whether the two 
proteins bind separately or as a complex to this promoter. 
Into the nuclear compartment, ΔNp63α and YB1 support 
PI3K/Akt signaling activation thereby increasing cell survival. 
On the other hand, Akt is known to blunt tumor cell invasion by 
blocking breast cancer cell motility through the inhibition of 
NFAT transcriptional activity (Yoeli-Lerner et al, 2005). Here we 
report that YB1 overexpressing tumor cells increase their speed 
by a factor 1.3 while decreasing persistence time by 
approximately 40%.  
Remarkably, we found that ΔNp63α expression restores a 
normal migratory behaviour with reduction in speed and 
simultaneous increase of persistence (figure 12c). Moreover, 
we have shown that ΔNp63α increases E-cadherin and 
restrains YB-1-dependent expression of pro-migratory genes 
such as Snail1 and Twist, thus counteracting cancer metastatic 
spread (Higashikawa et al., 2007). All together, our 
observations support the idea that ΔNp63α-YB1 association, in 
primary tumors, can act as a pro-survival mechanism while 
attenuating cell motility possibly explaining why ΔNp63α 
expression is selected against in highly metastatic carcinoma 
cells (Graziano et al., 2011). Such speculations however ought 
to be further investigated with invasion experiments performed 
in more ―physiologic‖ environments. 
Finally, although the generally accepted view is that YB-1 is 
preferentially expressed in cancer we have demonstrated that 
YB-1 is abundantly expressed in normal tissues such as 
primary keratinocytes and corneal epithelium and, in particular, 
in cells having a proliferating potential. 
Remarkably, frequent overlapping between p63 and YB-1 is 
detected in injury-activated corneas when stem cells are 
induced to develop into Transient Amplifying (TA) that divide a 
few times to regenerate the tissue and move to the suprabasal 
compartment. An intriguing possibility is that YB- 1 and ΔNp63α 
nuclear localization might be transiently induced by mechanical 
stress to promote resistance to anoikis, a cell death 
phenomenon involving epithelial cells induced by detachment 
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from the extracellular matrix, an aspect that can have important 
implications not only for cancer, but also for developmental and 
differentiation processes that are characterized by a precisely 
regulated balance between cell proliferation, migration and 
death. 
 
 
 
5. Materials and Methods 
 
Plasmids 
 
cDNA encoding human Flag-tagged YB1, YB1-S102A and YB1-
S102D were provided by Dr. Sandra Dunn (Research Institute 
for Children’s and Women’s Health, Vancouver, British 
Columbia, Canada). PIK3CA luciferase plasmid was provided 
by Dr Arezoo Astanehe (Research Institute for Children’s and 
Women’s Health, Vancouver, British Columbia, Canada). cDNA 
encoding human ΔNp63α and ΔNp63γ were previously 
described (Di Costanzo et al., 2009). For bacterial expression, 
ΔNp63γ and ΔNp63α cDNAs were inserted in pRSETA vector 
in XhoI/ClaI and XhoI/XbaI (filled) sites, respectively. GFP and 
YB1-GFP vectors were provided by Dr. Paul R. Mertens 
(University Hospital Aachen, Germany). PET-YB1 was from Dr. 
Jill Gershan (Medical College of Wisconsin, Milwaukee, 
Wisconsin). CA-Akt was a gift from Dr. G. Condorelli (IRCCS 
Ospedale San Raffaele, Milano). 
 
Cell lines, transfection and antibodies. 
 
MDA-MB-231, MCF7, HaCaT and H1299 cells were obtained 
from ATCC and maintained in DMEM supplemented with 10% 
fetal bovine serum at 37°C and 5% CO2. Dox-inducible Tet-On 
H1299/ΔNp63α cells were previously described (Lo Iacono et 
al., 2005). Lipofections were performed with Lipofectammine 
(Invitrogen), according to the manufacturer’s recommendation. 
YB1 transient silencing was carried out with ON-TARGET plus 
SMART pool YB1-siRNA (Dharmacon) and RNAiMAX reagent 
(Invitrogen). Anti-p63 (4A4) and anti-actin (1-19) were from 
Santa Cruz (Biotechnology Inc.), anti-FLAG M2 and anti-GFP 
(sc-8334) were from Sigma-Aldrich (Germany). PARP, Akt, pAkt 
(Ser473) and YB1 antibodies were from Cell Signaling 
Technology (Beverly, Massachussets). Anti-GFP antibody was 
from (Roche Applied Science). Mouse monoclonal E-cadherin 
(ab1416) and Snail1 antibodies were from Abcam (Cambridge, 
UK). Cy3-conjugated anti-mouse IgG was from Jackson 
(ImmunoResearch Laboratory, Inc, Pennsylvania). Doxycycline 
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was from Clonetech (Palo Alto, California). MG132 was from 
Calbiochem (San Diego, California). Cycloheximide was from 
Sigma (Sigma-Aldrich, Germany). 
 
Chromatin immunoprecipitation (ChIP) assay 
 
ChIP was performed with chromatin from human MDA-MB-231 
cells transfected with ΔNp63γ, ΔNp63α and/or FlagYB1, 
according to Radoja et al. (Radoja et al., 2007). Real Time PCR 
was performed with the 7500 Applied Biosystems apparatus 
and Syber Green MasterMix (Applied Biosystems) using the 
following oligonucleotides: 
PIK3CA-Forw CCCCCGAACTAATCTCGTTT 
PIK3CA-Rev TGAGGGTGTTGTGTCATCCT 
 
Immunoblot analyses and coimmunoprecipitation 
 
Immunoblots and coimmunoprecipitations were performed as 
previously described (Di Costanzo et al., 2009). To detect 
p63/YB-1 interaction in H1299 cells, 5.0 ×105 cells were plated 
in 60 mm dishes and transfected with 1μg of ΔNp63α or 
ΔNp63γ plasmids. For coimmuprecipitations, whole cell 
extracts, precleared with 30 μl of protein A-agarose (50% slurry; 
Roche, Manheim, Germany), were incubated overnight at 4°C 
with anti-YB-1(3 μg), anti-p63 (2 μg) or anti-Flag (3 μg). 
 
Far-western 
 
Far-western assays were conducted according to the protocol 
described by Cui S et al. 2004 Appropriate amounts of ΔNp63α 
or ΔNp63γ recombinant proteins were subjected to SDS–PAGE 
and transferred to PVDF membrane (Millipore, Milan, Italy). The 
bovine serum albumin (BSA) was used as control of unspecific 
binding, equal loading of BSA and recombinant YB1 or p63 
proteins in Far-Western blotting was verified by coomassie 
staining (data not shown). 
 
Luciferase reporter assay 
 
MDA-MB-231 cells were cotransfected with ΔNp63α, PIK3CA 
luc-promoter and pRL-TK. YB-1 gene silencing was carried out 
24 hrs before plasmid transfection. At 24h after transfection, 
cells were harvested in 1x PLB buffer (Promega) and luciferase 
activity was measured using Dual Luciferase Reporter system 
(Promega) using pRL-TK activity as internal control. FireFly-
derived luciferase activity was normalized for transfection 
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efficiency. Successful transfection of p63 and silencing of YB-1 
was confirmed by immunoblotting. 
 
RNA Immunoprecipitation 
 
1 x 106 MDA-MB-231 cells were seeded in 100mm plates and 
transfected with pcDNA3.1 or ΔNp63α espression vector. 24h 
after transfection, cells were fixed with 1% formaldehyde for 10 
min and washed twice in ice-cold PBS. Cell extracts were 
prepared in RNA-immunoprecipitation buffer (0.1% SDS, 1% 
Triton, 1mM EDTA, 10mM Tris pH 7.5, 0.5mM EGTA, 150mM 
NaCL) supplemented with complete protease inhibitor mixture 
(Sigma Chemical Co., St. Louis, MO, USA) and sonication was 
carried out with BANDELINE SONOPULSE HD2200 instrument 
under following conditions: 8 pulses of 4 sec at 0.250% of 
intensity. Cell extracts were incubated with anti-YB-1 (3μg) at 
4°C overnight. The RNA-protein immunocomplexes were 
precipitated with protein A beads (Roche) satured with tRNA 
and, after reverse cross-link, subjected to RealTime PCR. For 
PCR analysis total RNA was isolated using the RNA Mini 
Extraction Kit (Qiagen, GmbH, Hilden, Germany) according to 
the manufacturer’s instructions. Total RNA (1 μg) was used to 
generate reverse transcribed cDNA using SuperScript III (In 
Vitrogen Life technologies, Inc.). PCR analysis was performed 
with the following primers: 
Twist (F): 5’ AGAAGTCTGCGGGCTGTG 
Twist (R): 5’ TCTGCAGCTCCTCGTAAGACT 
YB-1 (F): 5’ CGCAGTGTAGGAGATGGAGAG 
YB-1 (R): 5’ GAACACCACCAGGACCTGTAA 
HPRT (F) : 5' CCT GCT GGA TTA CAT TAA AGC 
HPRT (R) : 5' CTT CGT GGG GTC CTT TTC 
The amplification sequence consisted of 30 cycles of 94°C/1’, 
55°C/1’, 72°C/1’. PCR products were resolved by 2% agarose 
electrophoresis. RT-PCR amplification results were analyzed by 
Quantity One software (Biorad). Real Time PCR was performed 
with a 7500 RT-PCR Thermo Cycler (Applied Biosystem) as 
already described ( Di Costanzo et al., 2010). HPRT was used 
for normalization. The results were expressed with the value 
relative to HPRT (set at 1) for each mRNA sample. For Snail1 
amplification we used Quantitect Primer Assay/Hs Snail1 from 
Quiagen. 
 
Immunofluorescence 
 
H1299, MDA-MB-231 or MCF7 cells (5.0 ×105) were plated in 
35 mm dish, grown on micro cover glasses (BDH) and 
transfected with 0.2 μg of pcDNAYB-1/GFP plasmid with or 
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without 0.6 μg of ΔNp63α or ΔNp63γ plasmid. The GFP vector 
transfected with ΔNp63α or ΔNp63γ encoding plasmids was 
used as control (data not shown). At 24 hrs after transfection, 
cells were washed with cold phosphate-buffered saline (PBS) 
and fixed with 4% paraformaldehyde (PFA) (Sigma-Aldrich, 
Germany) for 15 min at 4°C. Cells were permeabilized with ice-
cold 0.1% Triton X-100 for 10 min and then washed with PBS. 
P63 was detected by using a 1:200 dilution of the monoclonal 
antibody 4A4. After extensive washing in PBS, the samples 
were incubated with Cy3-conjugated anti-mouse IgGs at room 
temperature for 30 min. After PBS washing, the cells were 
incubated with DAPI (4′,6′-diamidino-2-phenylindole; 10 mg/ml 
[Sigma-Aldrich, Germany]) for 3 min. The glasses were 
mounted with Moviol (Sigma-Aldrich, Germany) and examined 
under a fluorescence microscope (Nikon). Images were digitally 
acquired and processed using Adobe Photoshop software CS3.  
 
Immunohistochemistry 
 
Human corneal tissues obtained from the Veneto Eye Bank 
Foundation (Zelarino-Venezia, Italy) were collected at different 
times, from 5 to 120 hours after death. The corneas were 
evaluated and divided into two groups: (1) normal corneas 
(typically fresh tissues), and (2) wounded corneas, as 
previously described by Di Iorio et al., 2005. The corneas were 
managed in accordance with the guidelines in the Declaration of 
Helsinki for research involving human tissue. They were fixed in 
3% paraformaldehyde (overnight at 4°C), embedded in optimal 
cutting temperature [OCT] compound, frozen, and sectioned (5- 
to 7−μm-thick slices). Sections were immunostained using 
antibodies against pan-p63 (4A4, mouse monoclonal, 1:100, 
BD Biosciences, Milan, Italy), keratin 12 (K12, sc-17099, goat 
polyclonal, 1:100; Santa Cruz Biotechnology, Santa Cruz, CA), 
and YB-1 (Cell Signaling Technology, Beverly, Massachussets, 
USA). Rhodamine and fluorescein isothiocyanate-conjugated 
secondary antibodies (1:100; Santa Cruz Biotechnology) were 
incubated for 1 h at room temperature. Specimens were 
analyzed with an LSM 510 Meta Confocal Microscope (Zeiss 
SpA, Milan, Italy). 
 
Time-lapse microscopy 
 
H1299 cells were cultured on 35 mm dishes (Corning, NY) at a 
density of 2×104 cells/dish. ΔNp63α expression was induced 
with 2 μg/ml doxycycline for 48 hr. 16 hr after transfection, cell 
dishes were placed in a mini-incubator connected to an 
automated stage of an optical microscope (Cell^R, Olympus 
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Co., Japan). Time zero images of selected position were 
collected in fluorescence in order to localize transfected cells. 
Then, at the same positions, images were recorded in 
brightfield (BF) every 10 minutes for 12 hours. BF images were 
mounted to obtain 72 frames time lapse video per each 
position. Cell trajectories were reconstructed from time lapse 
videos using Metamorph software (Molecular Device, CA). Root 
mean square speed (S) and persistence time (P), were chosen 
as relevant parameter in order to describe the macroscopic 
features of cell migration of the different experimental 
conditions. These parameters were calculated according to the 
procedure reported by Dunn (Dunn G.A, 1983). Briefly, mean-
squared displacement (MSD) of each cell, is calculated 
according to overlapping time intervals method (Dickinson RB 
and Tranquillo RT, 1993). Subsequently, S and P are estimated 
by fitting the experimental data of the MSD to a linear 
approximation of the persistent random walk model. The upper 
limit for the data fitting was set approximately at 200 min per 
each cell owing to the deviation from linearity that is observed 
at higher time points. The fitting procedure provided (S, P) pairs 
per each cells and Statistical significance between S and P 
values of the different experimental setups was assessed by 
performing a non-parametric Kruskal-Wallis test in Matlab 
(MathWorks, MA). p values < 0.05 were considered significant. 
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